Document:

Amended and Restated Development and Supply Agreement

 Exhibit 10.1 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 Confidential 
 AMENDED & RESTATED 
 DEVELOPMENT AND SUPPLY AGREEMENT

 By and Between 
 CADENCE PHARMACEUTICALS, INC. 
 and 

BAXTER HEALTHCARE CORPORATION 

 CONFIDENTIAL 
  

 TABLE OF CONTENTS 

							
			
	 1.0
	  	BACKGROUND	  	 	3	  
			
	 2.0
	  	DEFINITIONS	  	 	3	  
			
	 3.0
	  	COOPERATIVE ORGANIZATION	  	 	4	  
			
	 4.0
	  	DEVELOPMENT PLANS	  	 	5	  
			
	 5.0
	  	PRODUCT REGISTRATIONS AND USER FEES	  	 	8	  
			
	 6.0
	  	COMMERCIAL SUPPLY	  	 	9	  
			
	 7.0
	  	MANUFACTURING FEE	  	 	13	  
			
	 8.0
	  	API	  	 	15	  
			
	 9.0
	  	EQUIPMENT AND FACILITIES	  	 	17	  
			
	 10.0
	  	QUALITY MANAGEMENT	  	 	18	  
			
	 11.0
	  	MARKETING	  	 	21	  
			
	 12.0
	  	REPRESENTATIONS AND WARRANTIES	  	 	21	  
			
	 13.0
	  	CONFIDENTIALITY	  	 	24	  
			
	 14.0
	  	INTELLECTUAL PROPERTY	  	 	25	  
			
	 15.0
	  	INDEMNIFICATION	  	 	29	  
			
	 16.0
	  	ALTERNATE DISPUTE RESOLUTION	  	 	32	  
			
	 17.0
	  	FORCE MAJEURE	  	 	32	  
			
	 18.0
	  	RELATIONSHIP OF THE PARTIES	  	 	33	  
			
	 19.0
	  	TERM AND TERMINATION	  	 	33	  
			
	 20.0
	  	EFFECTS OF TERMINATION	  	 	34	  
			
	 21.0
	  	NOTICES	  	 	36	  

  

 CONFIDENTIAL 
  

							
	 22.0
	  	EXPORT	  	 	37	  
			
	 23.0
	  	MISCELLANEOUS	  	 	37	  

 EXHIBITS

  

			
	 EXHIBIT A
	  	PRODUCT SPECIFICATIONS
		
	 EXHIBIT B
	  	API SPECIFICATIONS
		
	 EXHIBIT C
	  	MINIMUM BATCH SIZES AND MANUFACTURING FEE
		
	 EXHIBIT D
	  	COST OF API AND METHODOLOGY FOR CALCULATING MANUFACTURING YIELD LOSSES
		
	 EXHIBIT E
	  	BAXTER OWNED EQUIPMENT
		
	 EXHIBIT F
	  	CADENCE OWNED EQUIPMENT
		
	 EXHIBIT G
	  	CONFIDENTIAL DISCLOSURE AGREEMENT
		
	 EXHIBIT H
	  	DEVEOPMENT PLAN TEMPLATE
		
	 EXHIBIT I
	  	DEFINITIONS

  
 2 

 CONFIDENTIAL 
  

 AMENDED AND RESTATED 

DEVELOPMENT AND SUPPLY AGREEMENT 
 This AMENDED AND RESTATED DEVELOPMENT AND SUPPLY AGREEMENT, (this “Agreement”) is effective as of January 28, 2011 (the “Effective Date”) by and between
CADENCE PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 12481 High Bluff Drive, Suite 200, San Diego, CA 92130 (“Cadence”) and BAXTER
HEALTHCARE CORPORATION, a corporation organized and existing under the laws of the State of Delaware and having its principal office at One Baxter Parkway, Deerfield, Illinois 60015 (“Baxter”). All references to
“Cadence” and “Baxter” will include their respective Affiliates. 
  

	1.0	BACKGROUND 

 Cadence has
an exclusive license to rights in the United States and Canada to a particular intravenous formulation of, and manufacturing process for, the Compound. 
 Baxter manufactures and markets sterile products in glass containers for parenteral administration of pharmaceutical preparations. 
 Cadence and Baxter entered into a Letter of Intent dated November 27, 2006, as amended (collectively, the “LOI”), and executed a Development and Supply Agreement dated July 18,
2007, as amended on October 11, 2007, March 1, 2009, October 15, 2009, and June 7, 2010 (collectively, the “Original Agreement”), with respect to the provision of certain development and commercial
supply services by Baxter. 
 The Parties now wish to modify the terms of the Original Agreement to confirm the terms and
conditions under which Baxter will manufacture the Product for commercial distribution, and establish the terms and conditions under which the commercial manufacturing capacity for the Product at the Facility will be expanded. Upon the Effective
Date, the LOI and the Original Agreement shall be superseded in their entirety by this Agreement. 
 THEREFORE, the Parties,
intending to be legally bound, agree as follows: 
  

	2.0	DEFINITIONS 

 Certain
capitalized terms used in this Agreement and not otherwise defined herein have the meanings assigned to them in Exhibit I. 

  
 3 

 CONFIDENTIAL 
  

	3.0	COOPERATIVE ORGANIZATION 

In order to facilitate collaboration between the Parties to achieve the objectives of this Agreement, the Parties agree to the following
organizational provisions: 
 3.1 Product Manager. Baxter and Cadence will each identify an individual(s) with
appropriate authority to serve as the primary contact with the other Party about the Product and the Parties’ relationship under this Agreement (each a “Product Manager”), who will be responsible for obtaining cooperation and
input from other individuals within such Product Manager’s organization whose expertise and ability may be required from time to time to ensure the success of the collaboration between the Parties under this Agreement. 

3.2 Steering Committee. The Parties shall establish a steering committee, consisting of at least one general business executive
and one senior technical executive from both Parties (“Steering Committee”). The Steering Committee will meet at least quarterly, through face-to-face meetings at a mutually convenient location or via telephone conferences and/or
videoconferences, at times to be mutually agreed. The Steering Committee will discuss and resolve any overarching questions or issues and discuss future plans and the relationship between the Parties. The Steering Committee shall not have the
authority to modify, supplement, amend or terminate this Agreement. If the Steering Committee is unable to resolve any such differences, the matter(s) shall be escalated to the Chief Commercial Officer for Cadence and the VP, Sales for Baxter
BioPharma Solutions for Baxter (the “Senior Executives”). If the Senior Executives are unable to resolve any such differences, the matter shall be handled pursuant to Article 16.0 of this Agreement. 

3.3 Cadence Product Manager in Facility. Baxter agrees to provide office accommodations in its Facility, on the conditions set
forth below, to the Cadence Product Manager or his/her designee, specializing in manufacturing processes. Baxter may, in its sole discretion, at any time, revoke its offer to provide office space in its Facility for a specific individual serving as
Product Manager or his/her designee, or for the Cadence Product Manager position, following sixty (60) days’ prior written notice to Cadence. 
 3.3.1 The Cadence Product Manager (and any designee) shall on an annual basis agree to (i) undergo training on Baxter’s security, safety, and emergency procedures at the Facility, (e.g.
site evacuation procedures) within a timeframe agreed to between Cadence and Baxter’s Facility Management team, (ii) undergo training on GMP requirements and specific site interpretations and application, and (iii) abide by all
training requirements. Training requirements specified above will be documented by Baxter in a written communication, with a training plan and timeframe for completion agreed to by the Parties. The completion of the training will also be documented
in written communication to Cadence. 
 3.3.2 In order to protect the confidentiality of Baxter and any third parties,
Baxter Facility personnel may restrict the Cadence Product Manager position’s access to certain conference rooms or other areas at the Facility. In general, the Cadence Product Manager position’s access shall be limited to those areas
relevant to the manufacture of the Product. In the event Baxter designates certain areas as restricted to the Cadence Product Manager position, the Cadence Product Manager and any designee agree not to enter such areas. 

  
 4 

 CONFIDENTIAL 
  

	4.0	DEVELOPMENT PLANS 

  

	 	4.1	Development Plans 

4.1.1 NDA Development Plan. The Parties acknowledge the completion of the NDA Development Plan concurrent with the approval of an
NDA for the Product by the FDA on November 2, 2010. 
 4.1.2 Capacity Increase Development Plan. Within sixty
(60) days after the Effective Date, or such longer time period as may be mutually agreed upon by the Parties, the Parties will mutually agree upon a development plan (using the development plan template attached as Exhibit H or a
substantially similar form) for the expansion of the manufacturing capacity for the Product at the Facility (the “Capacity Increase Development Plan”). The Capacity Increase Development Plan will identify in detail the scope of the
activities to be performed and the fees associated with such activities. All capital equipment and Facility improvements included therein will be funded by Cadence. The Capacity Increase Development Plan will also include provisions detailing the
process by which Baxter will agree to accept the completed, validated second manufacturing line for the Product to be installed at the Facility. The Parties agree to work together to resolve in good faith any outstanding disagreements with respect
to the Capacity Increase Development Plan and, following approval by both Parties, the Capacity Increase Development Plan shall be incorporated by reference as part of this Agreement. Each Party shall use Commercially Reasonable Efforts to timely
accomplish the tasks that it is assigned under the Capacity Increase Development Plan. 
 4.1.3 Additional Development Plans.
The Parties may, from time to time, mutually agree upon one or more development plans (using the development plan template attached as Exhibit H or a substantially similar form), which will identify in detail the scope of the activities
to be performed and the fees associated with the activities (each, a “Development Plan”). Cadence will initiate each new Development Plan and send the draft Development Plan to Baxter for review and comment. The Parties agree to
work together to resolve in good faith any outstanding disagreements with respect to each Development Plan. Unless otherwise agreed in writing by a duly authorized representative of each Party, in no event shall Baxter purchase any Materials or
equipment or schedule or commence any work, and Baxter shall not be obligated to do so, until a Development Plan has been fully executed by both Parties. Each executed Development Plan shall be incorporated by reference as part of this Agreement.
Each Party shall use Commercially Reasonable Efforts to timely accomplish the tasks that it is assigned under each Development Plan. 

  
 5 

 CONFIDENTIAL 
  

 4.2 Provisions Generally Applicable to Development Plans. The activities and key
milestones to occur with respect to each Development Plan may include, but are not limited to, the following activities or topics: (i) technical feasibility assessment, (ii) formulation and analytical development, (iii) Facility
improvements, (iv) equipment and Material purchases, (v) clinical scale production, (vi) stability studies and Product batch production to support Regulatory Submissions, (vii) Regulatory Submissions, (viii) Regulating
Groups’ review and approval, and (ix) Product launch readiness activities and other pre-commercial activities. If different from the Product Specifications, specifications applicable to Product to be manufactured under each Development
Plan will be set forth in each such plan, subject to refinement from time to time based upon the results of the Development Plan, the results of ongoing activities under other Development Plans, and requirements of Regulating Groups. While Product
and Formulation specifications, and any changes thereto, must be agreed to in writing by both Parties, Cadence will be responsible for and must provide final approval of all Product specifications and any Formulation specifications included in
Development Plans, and all changes thereto prior to implementation. 
 During the Term of the Agreement, Cadence will be
responsible for performing certain Cadence activities as set forth in each Development Plan, including but not limited to, the following: (i) providing technical information about the API and the manufacturing process for Product,
(ii) unless otherwise agreed in writing by a duly authorized representative of each Party, timely providing the API and applicable reference standards required for implementation of the activities described in the Development Plans,
(iii) unless otherwise agreed between the Parties, compliance with Regulatory Submission reporting requirements regarding manufacture and control of the API, (iv) timely review, drafting and filing of all necessary submissions with
Regulating Groups, and (v) payment of development fees and other fees and expenses as set forth in Section 4.2.3. 

In general, during the Term of the Agreement, Baxter will be responsible for performing certain activities as set forth in each
Development Plan, including but not limited to, the following: (a) conducting development studies identified as a Baxter Development Deliverable in each Development Plan, (b) maintaining inventories of excipients, applicable reference
standards and other components and Materials required as agreed in each Development Plan for timely implementation of the activities described therein, (c) manufacturing Product for Regulatory Submissions and as otherwise provided in each
Development Plan and pursuant to the applicable Regulatory Strategy, (d) preparing those portions of necessary submissions with Regulating Groups consistent with Baxter’s obligations under the applicable Regulatory Strategy, and
(e) supporting Cadence in its efforts to obtain and maintain approval of the Regulating Groups to sell the Product in the Territory. 
 4.2.1 Development Deliverables. Baxter will promptly disclose to Cadence during the Term of the Agreement, in English and in writing, all Baxter materials set forth in the Development Plans
(“Baxter Development Deliverables”) which will include such interim progress reports and final reports as may be agreed upon by the Parties. Cadence will promptly disclose to Baxter during
the Term of the Agreement, in English and in writing, all Cadence materials set forth in the Development Plans (“Cadence Development Deliverables”). 

  
 6 

 CONFIDENTIAL 
  

 4.2.2 Additional Development Deliverables. If the Baxter Development Deliverables
or the Cadence Development Deliverables set forth in a Development Plan prove to contain insufficient information for a Party to carry out its responsibilities under this Agreement, including information required for Cadence to obtain and maintain
Regulating Group approval and registration of the Product in the Territory in accordance with Article 5.0 or to complete the FDA’s Annual Report and similar reports required by other Regulating Groups, or to obtain Patent protection in
accordance with Article 14.0, the Parties will in good faith negotiate and execute an Amended and Restated Development Plan to include as a Deliverable the additional information or activities which are necessary for such purpose. Such negotiations
may arise by mutual consensus of the Parties or following the written request of either Party. Baxter will not be required to perform, nor be entitled to reimbursement for, any work beyond that described in a Development Plan(s) unless and until the
Parties reach written agreement on the scope of any additional work and the related additional expenses (coordinated through the Product Managers under Section 3.1), and an Amended and Restated Development Plan has been executed by both
Parties. 
 4.2.3 Payment of Development Fees and Costs. Development fees payable by Cadence to Baxter for the Baxter
Development Deliverables as set forth in each Development Plan, costs for Material and equipment purchases and Facility improvements, and any other fees and expenses agreed upon by the Parties as set forth in a Development Plan, will be paid by
Cadence in United States dollars within thirty (30) days after the date of Cadence’s receipt of each invoice from Baxter following completion of the designated activities. Baxter agrees that all such invoices will be provided to Cadence on
a timely basis, which shall in no event be later than sixty (60) days following the date on which Baxter incurs any such fees or expenses, and shall contain a reference to the Development Plan to which the invoice relates. Invoices not timely
paid will be subject to a late payment charge of one and one-half percent (1-1/2%) per month, or the highest rate allowed by law if lower, until paid in full. If any portion of an invoice is disputed, then Cadence shall pay the undisputed
amounts as set forth in the preceding sentence and the Parties shall use good faith efforts to reconcile the disputed amount within (60) days of receipt; provided, that Cadence shall not be obligated to pay any late payment fee on any
such amount disputed in good faith. 
 4.3 Regulatory Strategies. Cadence shall be solely responsible any regulatory
strategies and considerations associated with each Development Plan. Any development or regulatory-related activities required to be undertaken by Baxter in support of Cadence’s regulatory strategies associated shall be set forth in each
Development Plan. Cadence may revise its regulatory strategies for any Development Plan, subject to prior written agreement between the Parties in the event that any such change is reasonably anticipated to impact the cost and timetable of the
development or regulatory-related activities specified in the Development Plan. Cadence will discuss with Baxter any elements of its regulatory strategies which may reasonably be expected to have an impact on Baxter’s obligations under this
Agreement. 

  
 7 

 CONFIDENTIAL 
  

 4.4 Stability Studies. Baxter shall perform at no additional cost to Cadence on
an on-going basis one (1) annual stability study required by the Specifications, Applicable Laws, and the NDA for the Product, and the Quality Agreement in connection with the manufacture of the Product. 

4.5 Technical Issues. The Parties acknowledge and agree that, as a result of the approval of an NDA for the Product by the FDA,
the terms “Technical Failure” and “Integration Failure” (as defined in the Original Agreement) are no longer applicable to this Agreement. 
  

	5.0	PRODUCT REGISTRATIONS AND USER FEES 

 5.1 Product Registration Application Ownership. Cadence will be the sole owner of any registration applications submitted to Regulating Groups for the Product. Cadence will have responsibility for
the documentation and submission of the registration applications to Regulating Groups and for completing the FDA Annual Report and similar reports required by other Regulating Groups, with support from Baxter in providing any information required
from Baxter in order to complete such reports. Communications to and from the Regulating Groups that involve the NDA or any other Regulatory Submissions are subject to the provisions of Section 5.3. 

 

	 	5.2	Product Registration and User Fees. 

 5.2.1 Right of Reference – Drug Master File. Baxter acknowledges that it holds DMF [***]. Baxter will provide a letter of authorization for DMF [***] to Cadence to support the container
closure system and parametric release of the Product in lieu of end-product testing. The right of reference does not include Cadence access to DMF [***]. In the event of a critical regulatory issue with the Product, such as a product recall, Baxter
will provide appropriate data, technical reports, and other information to Cadence regarding the issue, including information that may reside in DMF [***]; provided, however, that Baxter reserves the right to redact to protect its
Confidential Information or the confidential information of third parties. 
 5.2.2 Additional Filing Data. During the
Term of the Agreement, Baxter will, following prior written review and approval of Cadence, provide the Regulating Groups such additional data and information related to the Product as are required for Cadence to obtain and maintain registration and
approval of the Product in good standing in the Territory, including without limitation, Pre-Existing Specifications, Baxter Background Intellectual Property Rights and Original Product Data. Baxter reserves the right to inform the Regulating Groups
that such information is confidential and to advise the Regulating Groups that Cadence will be entitled to reference such information on a confidential basis during the Term of the Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 8 

 CONFIDENTIAL 
  

	 	5.3	Communications to/from Regulating Groups. 

 5.3.1 Communications from Regulating Groups. Each Party will promptly notify the other Party of any communication from Regulating Groups related to the Product or the activities of the Parties
contemplated under this Agreement (collectively, “Communication(s)”). Each Party reserves the right to redact its Confidential Information or confidential third party information. 

5.3.2 Communications to Regulating Groups. In the event that a response to a Regulating Group is required in connection with any
Communication, the Parties will use reasonable efforts to agree on which individuals need to collaborate on such responses. Cadence will have primary responsibility to respond to all Communications from Regulating Groups in connection with any
Cadence Regulatory Submission regarding the Product (including the vial, stopper, cap and all labeling for the Product), the API or the Formulation, and any non-Product specific information related to Cadence, and Baxter will have primary
responsibility to respond to all Communications from Regulating Groups in connection with DMF [***], the Facility, container closure integrity and sterility assurance for the Product, and any non-Product specific information related to Baxter. Each
Party will collaborate in good faith with the other Party in preparing such responses, and Baxter will provide Cadence with information that the Parties reasonably agree is required to develop a requested response for questions directed to any
Cadence Regulatory Submission or other Communication. In the event that Baxter and Cadence are unable to agree on the final content of any such response, then Cadence’s position will prevail as it pertains to all Communications sent to
Regulating Groups relating to the API, Formulation, or the Product (including the vial, stopper, cap and all labeling for the Product), and Baxter’s position will prevail as it pertains to DMF [***], the Facility, container closure integrity
and sterility assurance for the Product. If requested, Baxter will allow an agreed upon third party to review redacted portions of DMF [***] where information is required to be shared with Regulating Groups pertaining to the Product; provided,
however that Baxter has the ability to set reasonable conditions upon the review parameters and to protect its Confidential Information and the confidential information of third parties. 

5.4 User Fees. Cadence will pay all user and/or filing fees charged to Cadence by Regulating Groups that relate to the
registration application and ongoing marketing of the Product, including, but not limited to, the Application Fee, the annual Drug Product Fee, and a portion of the Drug Establishment Fee. 

 

	6.0	COMMERCIAL SUPPLY 

  

	 	6.1	Product Standards, Specifications and Materials. 

 6.1.1 Standards. Baxter shall manufacture, test, package, store, label, release and deliver the Product in accordance with the Product Specifications, Applicable Laws, the NDA for the Product, and
the Quality Agreement. Baxter shall also maintain the Facility in compliance with all Applicable Laws and the Quality Agreement, and shall be responsible for all costs and expenses related to the maintenance of the Facility in compliance therewith.

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 9 

 CONFIDENTIAL 
  

 6.1.2 Product Specifications. Exhibit A includes Product Specifications in
effect as of the Effective Date. The Quality Agreement shall govern the procedures for making changes to Product Specifications for commercial Product. Cadence will be responsible for and must provide final approval of Product Specifications and all
changes thereto prior to implementation. 
 6.1.3 Materials. Baxter shall procure the Materials at such times, and in
such amounts consistent with the amounts forecasted per Section 6.3 and as shall be necessary in order for Baxter to timely produce and deliver the Product as requested by Cadence in accordance with this Agreement. Both Parties agree to work
together to reduce lead time for orders and deliveries of the Materials. Baxter shall obtain the Materials only from suppliers listed in the NDA for the Product, where applicable, and shall perform all testing of Materials required by the Product
NDA for the Product or Quality Agreement. Audit and qualification of third party suppliers of raw Materials shall be handled in accordance with the Quality Agreement. 
 6.1.4 Label Copy. All label copy and changes therein, on the Product label itself and other label copy that Cadence uses to market Product in the Territory, will be the responsibility of Cadence.
Any Product label affixed by Baxter to a Product shall be in the form most recently approved by Cadence. 
 6.2 Supply and
Purchase Obligations. Baxter will be the supplier for, and Cadence will purchase from Baxter, [***] units of the Requirements during each Contract Year during the Initial Term. Additionally, Baxter will be the supplier for, and Cadence will
purchase from Baxter, [***] units of the Requirements during each Contract Year, if any, following the Initial Term. 
 6.2.1
Notwithstanding Cadence’s obligation to purchase [***] units of the Requirements from Baxter during each Contract Year during the Initial Term, or [***] units of the Requirements during each Contract Year following the Initial Term, as
applicable: 
 6.2.1.1 If Baxter has failed to provide at least [***] percent ([***]%) of the quantity of Product in
accordance with each Firm Purchase Order (including, without limitation, within the delivery time frames set forth in such Firm Purchase Orders) during any [***] period, Cadence may purchase from other suppliers the Product that Baxter failed to
deliver and such quantity will be deducted from the [***] units, or from the [***] units, as applicable, of the Requirements that Cadence is obligated to purchase for that Contract Year under Section 6.2.1; and 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 10 

 CONFIDENTIAL 
  

 6.2.1.2 If, despite the collaboration of the Parties under Section 6.3,
Baxter has not accepted (pursuant to Section 6.4.2, below) and committed to timely provide to Cadence at least [***] ([***]%) of the quantity of Product included in each purchase order submitted by Cadence to Baxter in accordance with
Section 6.4.1 for any [***] period, Cadence may purchase from other suppliers the Product that Baxter has not committed to timely supply, and such quantity will be deducted from the [***] units, or from the [***] units, as applicable, of the
Requirements that Cadence is obligated to purchase for that Contract Year under Section 6.2.1. 
 6.2.2 Minimum Purchase
Requirement. During the Initial Term, Cadence shall purchase from Baxter, at a minimum, the number of units of Product for each Contract Year as set forth below (“Minimum Purchase Requirement”): 

 

			
	 Contract Year Commencing:
	  	Units (Million)
	          Nov. 1, 2010	  	[***]
	          Nov. 1, 2011	  	[***]
	          Nov. 1, 2012	  	[***]
	          Nov. 1, 2013	  	[***]
	          Nov. 1, 2014	  	[***]
	Each additional year (if any)	  	[***]

 These units will be ordered in the
Minimum Batch Size. If Cadence fails to purchase the Minimum Purchase Requirement in any Contract Year, within thirty (30) days after the end of each Contract Year, Cadence shall pay Baxter an amount equal to the Manufacturing Fee multiplied by
the shortfall in units. Cadence shall not be obligated to pay any shortfall amount if Cadence’s failure to meet the Minimum Purchase Requirement is due to Baxter’s inability to timely supply Cadence with its Requirements of Product in the
applicable Contract Year and Baxter’s inability to timely supply such Requirement is not due to Cadence’s failure to meet its obligations under this Agreement. 
 6.3 Forecasts. In order to assist Baxter in its production planning of Product for Cadence, Cadence will provide to Baxter, at least ninety (90) calendar days before the beginning of each
calendar quarter during the Term of the Agreement, rolling twelve (12) month forecasts of Cadence’s estimated Product requirements (“Estimated Requirements”) and expected monthly requirements for Product during such
forecast period. Cadence and Baxter will collaborate in good faith, using the Estimated Requirements, to plan for production such that substantial increases or decreases in production may, generally, be spread gradually over each Contract Year;
provided, however, the Cadence’s actual market demand for the Product shall in all cases take precedence over any such scheduling agreements. Cadence will make such Estimated Requirements in good faith given market
conditions and other information available to Cadence, but such Estimated Requirements shall not be binding on Cadence or Baxter except as provided in Section 6.4.3.  

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 11 

 CONFIDENTIAL 
  

	 	6.4	Purchase Orders; Firm Purchase Orders. 

 6.4.1 General. During the Term of the Agreement and upon the terms and conditions set forth in this Agreement, Baxter shall, or shall cause its Affiliates to manufacture, or cause the manufacture
of, and supply to Cadence the Product, ordered pursuant to the process set forth in this Section 6.4, including, but not limited to volume variations and subject to the restrictions set forth herein. Cadence will place purchase orders for the
portion of its Requirements for Product required during each calendar quarter at least ninety (90) calendar days prior to the beginning of each such calendar quarter. Each purchase order will specify the individual Product order quantities by
month for the quarter. Purchase orders will be placed in increments of no less than the Minimum Batch Size. Baxter will confirm its ability, or inability, to provide Product in the month for which Cadence has requested delivery as further set forth
in Section 6.4.2. Subject to the provisions of Section 6.2, all such purchase orders will not be less than [***] percent ([***]%) nor more than [***] percent ([***]%) of Cadence’s most recently updated Estimated Requirements for
Product for such calendar quarter. 
 6.4.2 Acceptance. Within ten (10) days, Baxter will accept or reject each
purchase order received from Cadence by providing a written notice confirming its ability to manufacture the quantity of the Product specified therein, and including the associated price and month within which the manufacture of the Product will
occur. For the purposes of this Agreement each purchase order accepted by Baxter and each purchase order which is neither accepted or rejected by Baxter within ten (10) days of Baxter’s receipt of same, shall be a “Firm Purchase
Order.” Baxter shall supply Product pursuant to each Firm Purchase Order, provided, that each Firm Purchase Order shall be deemed to have been fully satisfied if the quantity of each of the Product supplied thereunder is not more
than [***] percent ([***]%) and not less than [***] percent ([***]%) of the quantity of Product ordered therein. 
 6.4.3
Cancellations and Rescheduling. Notwithstanding the foregoing Section 6.4.1: 
 6.4.3.1 Baxter will use
Commercially Reasonable Efforts to comply with any of Cadence’s unplanned changes in Firm Purchase Orders, but will not be held liable for its inability to do so; 
 6.4.3.2 Cadence may cancel a Firm Purchase Order, subject to the payment of a cancellation fee of [***] percent ([***]%) of the amount of any such cancelled Firm Purchase Order penalty if Cadence
notifies Baxter of such cancellation within [***] days of the date on which Baxter had scheduled the manufacture such Product; and 
 6.4.3.3 Cadence may reschedule a Firm Purchase Order, subject to the payment of a rescheduling fee of [***]% of the amount of any such rescheduled Firm Purchase Order if Cadence notifies Baxter of
such rescheduling within [***] days of the date on which Baxter had scheduled the manufacture such Product. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 12 

 CONFIDENTIAL 
  

 6.4.4 Forms. The terms and conditions of this Agreement will be controlling over
any terms and conditions included in any purchase order form used in ordering Product. Any term or condition of such purchase order form that is in addition to, different from or contrary to the terms and conditions of this Agreement will be void,
unless the Parties otherwise agree by a separate written agreement. 
 6.5 Delivery; Shipment. All Product supplied under
this Agreement will be delivered FCA Baxter’s distribution site in Memphis, Tennessee. Baxter will make shipping arrangements with the appropriate carriers designated in writing by Cadence from the FCA point, under the agreements that Cadence
has with those carriers on or before the delivery date. Baxter shall be responsible for loading the Products to be shipped with the designated carrier. 
 6.6 Title/Risk of Loss. Title to and risk of loss with respect to the Product shall pass from Baxter to Cadence when picked up by the carrier at the Facility. All Products delivered to Cadence
shall be free and clear of any liens and encumbrances. 
 6.7 Exporter of record. Cadence will be deemed the exporter of
record for Product shipped outside of the United States (which should only occur to the extent such areas are included in the definition of “Territory”). Cadence warrants that all shipments of Product outside the United States will be in
compliance with all applicable United States export laws and regulations, including the Export Administration Act, and all applicable import laws and regulations. 
  

	7.0	MANUFACTURING FEE 

 7.1
Manufacturing Fee. Baxter will invoice Cadence a Manufacturing Fee per unit of Product in the amount set forth in Exhibit C, upon release to finished goods inventory of Product that has been quality control released by Baxter in
accordance with the chemistry, manufacturing, and controls (CMC) information in the NDA for the Product and Product Specifications, as may be amended from time to time. The Quality Agreement shall ultimately govern release of Product for delivery to
Cadence. 
  

	 	7.2	Adjustments to Manufacturing Fee. 

 7.2.1 Effective upon the commencement of each Contract Year beginning on November 1, 2011, Baxter will increase the Manufacturing Fee by an amount equal to $[***] per unit or [***], whichever
is greater. Baxter will provide Cadence with written notice ninety (90) days prior to the effective date of any such increase in the Manufacturing Fee, which notice shall set forth the amount and basis for such increase. 

7.2.2 Effective upon the commencement of each Contract Year beginning on November 1, 2011, the Manufacturing Fee may be
adjusted by Baxter to reflect an increase or decrease, as the case may be, in the cost of Material required to manufacture the Product, 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 13 

 CONFIDENTIAL 
  

 
provided, however, that any such increase or decrease in Material cost is greater than [***] percent ([***]%) of the average cost to purchase such Material during the previous Contract
Year. Baxter will provide Cadence with written notice ninety (90) days prior to the effective date of any such increase or decrease in the Manufacturing Fee, which notice shall set forth the amount and basis for such increase or decrease.

 7.2.3 Additionally, the Manufacturing Fee will be reduced, on a “pass-through” basis, to reflect the
decrease, if any, in the cost of any Material that results from any cost concession, volume purchase commitment, or other negotiation with the supplier of such Material by Cadence or on Cadence’s behalf. All such cost decreases will be applied
to the Manufacturing Fee at the time that the Material to which the cost decrease applies is first used to manufacture the Product. 
 7.3 Additional Work and Fees. The Manufacturing Fee described in Section 7.1 is based upon the scope of activities that Baxter plans to undertake in the ordinary course to manufacture and
release Product in accordance with the Exhibits hereto, Applicable Laws and the Quality Agreement. The Manufacturing Fee does not cover activities or expenses related to matters that might arise outside the ordinary course of manufacturing and
releasing Product in accordance with the Product Specifications, Applicable Laws, Quality Agreement, and other Exhibits. By way of example only, additional work might be required for Product or process changes requested by the Regulating Groups, API
source changes or API manufacturing process changes, USP or other regulatory requirements changes, excessive or untimely requests by Cadence for label changes or recalls or other actions by Regulating Groups, or mutually agreed upon expansion of the
Territory. Baxter will not be required to perform, nor be entitled to reimbursement for, any such work until the Parties negotiate in good faith and reach written agreement on the scope of the additional work and the related additional expenses. Any
such additional work and the related additional expenses shall be set forth in a Development Plan. 
 7.4 Improvement
Initiatives. From time to time either Baxter or Cadence individually or Baxter and Cadence working collaboratively may propose changes to the Normal Manufacturing Process that result in improvements to efficiency, throughput, Product quality,
Materials cost or other benefits to either or both of the Parties (“Improvements”). 
 7.4.1 Cadence may at any
time request Improvements, provided, that Cadence and Baxter agree to a Development Plan to the Development Agreement that details the project to implement the Improvement, and provided, that the Improvement does not adversely affect
Facility operations or lead to major process changes outside of the Cadence Owned Equipment. Any costs and expenses of such Improvements, as well as any cost savings that result from the Improvement, shall be allocated as mutually agreed in writing
between the Parties in the Development Plan. To be clear, the percentage split between the Parties of the actual savings attributed to Improvements requiring capital investment to the Facility shall be agreed upon at the time that such capital
investments are proposed. Ownership of the capital equipment and capital improvements resultant from such capital investment shall also be agreed upon at the time that the capital improvements are proposed. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 14 

 CONFIDENTIAL 
  

 7.4.2 Baxter may implement Improvements of its own and sole initiative, provided,
that any such Improvements initiated by Baxter shall only be made in accordance with Section 10.8, and provided, that any such Improvement shall be made at Baxter’s sole cost and expense. To be clear, any costs savings as may be
realized by Improvement of the sole initiative and expense of Baxter shall accrue exclusively to Baxter. 
 7.5 Payment; Late
Payment Charges. Cadence will pay the Manufacturing Fee (under Section 7.1), expenses for additional work (under Section 7.3), maintenance-related costs (under Section 9.4), and costs associated with de-installation and
restoration (under Sections 20.4, 20.5 and 20.6) and any other amounts owed to Baxter under this Agreement, in United States dollars within thirty (30) days after the date of Baxter’s invoice, by wire transfer in United States dollars, to
a bank account designated in writing by Baxter. Invoices not timely paid will be subject to a late payment charge of [***] percent ([***]%) per month, or the highest amount permitted by law, if lower. Notwithstanding the foregoing, should Cadence
give Baxter a Deficiency Notice pursuant to Section 10.2, Cadence’s obligation to pay under this Section 7.5 shall be suspended until the Parties have mutually agreed upon a resolution of the deviation(s) underlying any such
Deficiency Notice. 
  

	8.0	API. 

 8.1 General.
Cadence will, at its cost, supply API to Baxter at the Facility. API will be supplied timely, in adequate quantities to enable Baxter to meet its obligations to develop and manufacture the Product in accordance with the terms of this Agreement, all
in conformance with the API Specifications set forth in Exhibit B, as may be amended by Cadence from time to time. Baxter and Cadence will agree on appropriate inventory levels for API and Product and Baxter will manage these inventory
levels. Cadence will retain title to the API while it is in Baxter’s possession. Baxter will not use the API supplied by Cadence for any purposes other than pursuant to the terms of this Agreement. Cadence is responsible for the quality and
control of any API provided by Cadence and the API Specifications. Cadence is also responsible for the quality and control of any other components or raw Materials provided by Cadence to Baxter, including without limitation, the suppliers of such
components and raw Materials and the related specifications. 
 8.2 Change of API Source or API Manufacturing Process.
Cadence agrees to provide written notice to Baxter of any proposed change to the API source, or any change in the manufacturing process for the API as soon as possible (e.g., upon receipt of notice from their supplier.) Following such written notice
to Baxter, the Parties will work together to promptly agree upon a Development Plan with respect to any work reasonably required of Baxter to support Cadence’s filings with the Regulating Groups to obtain approval for such change. Under

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 15 

 CONFIDENTIAL 
  

 
any such Development Plan, Cadence will reimburse Baxter for all reasonable costs incurred by Baxter directly related to work performed by Baxter in support of such API source or API
manufacturing process change, including but not limited to the cost of new stability studies, submissions to the FDA and any other Regulating Groups and return of unused (if any) API from the prior source or manufactured under prior API
manufacturing processes. Except pursuant to a Development Plan agreed upon by the Parties, Baxter shall not be required to manufacture the Product using API from a new source or API that has been manufactured using an API manufacturing process that
has been modified such that approval by the Regulating Groups is required in order to market, sell and distribute the Product in the Territory, unless and until such change is approved by applicable Regulating Groups. 

8.3 Risk of Loss of API. Subject to Section 12.2.1, Baxter will have the risk of loss or damage to the API from the time the
API is delivered to the Facility and during the storage thereof. In the event of loss or damage to the API during such period, Baxter will immediately notify Cadence and Cadence will provide to Baxter API required for replacement thereof at the
actual replacement cost of the API paid by Cadence to its supplier including duty, freight and testing costs. Cadence will provide to Baxter appropriate documentation evidencing such costs. 

If the loss or damage occurred other than during the performance of the Normal Manufacturing Process, then Baxter shall pay Cadence for
such replacement API in an amount equal to the actual cost paid by Cadence for such API, plus duty, freight and testing costs. 

Per Section 8.4, if the loss or damage occurred during the performance of the Normal Manufacturing Process, the amount of API lost
or damaged will be included in the annual yield loss calculation and a determination will be made at the end of the relevant Contract Year as to what amount, if any, is owed by Baxter to Cadence for such loss of API. 

Notwithstanding the foregoing, Baxter shall not be required to pay Cadence to replace reasonable amounts of API that are consumed in the
course of testing required for incoming receiving and inspection. 
 Baxter will pay amounts owed to Cadence under this
Agreement, including without limitation amounts owed under Sections 8.3.1 and 8.3.2, in United States dollars within thirty (30) days after the date of Cadence’s invoice, by wire transfer in United States dollars, to a bank account
designated in writing by Cadence. Invoices not timely paid will be subject to a late payment charge of [***] percent ([***]%) per month, or the highest amount permitted by law, if lower. 

8.4 Manufacturing Yield Losses. The actual yield loss percentage for each Contract Year shall be calculated, reconciled, and
agreed to by Cadence and Baxter within forty-five (45) days following the end of each Contract Year. Baxter will be responsible for calculating actual yield loss percentage as per the methodology set forth in Exhibit D, which is

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 16 

 CONFIDENTIAL 
  

 
being provided for illustrative purposes. The Parties acknowledge and agree that any and all losses occurring other than during the performance of the Normal Manufacturing Process or any loss due
to improper handling, storage or due to any negligence on the part of Baxter will not be included in the annual yield loss calculation, but will be reimbursed to Cadence in accordance with Section 8.3.1. 

 

	9.0	EQUIPMENT AND FACILITIES 

9.1 Compliance with Applicable Laws. Baxter shall at all times during the Term of the Agreement maintain the Facility and all other
Baxter locations that provide services under this Agreement in compliance with Applicable Laws. Baxter shall be responsible for all costs and expenses required to maintain the Facility and such other Baxter locations in compliance with Applicable
Laws, provided, however, that if Facility, equipment, process, or system changes are necessary in order to maintain compliance with Applicable Laws, and if the changes would not be necessary but for Baxter’s manufacturing
activities for the Product, then, upon Cadence’s agreement with the necessity for such changes and the reasonableness of the anticipated costs and expenses, Cadence shall bear such costs and expenses in accordance with this Agreement. Baxter
shall notify Cadence promptly if it reasonably determines that any such changes are required and will include in any such notification the anticipated costs and expenses associated with such changes. 

9.2 Baxter Owned Equipment and Risk of Loss. All equipment supplied, owned or purchased by Baxter and paid for by Cadence as of
the Effective Date is set forth in Exhibit E (“Baxter Owned Equipment”). The Baxter Owned Equipment shall at all times remain the property of Baxter and Baxter assumes the risk of loss of such property. Baxter hereby waives
any and all rights of recovery against Cadence, or against its directors, officers, employees, agents or representatives, for any loss or damage to Baxter Owned Equipment, except if such loss or damage is caused by Cadence’s gross negligence or
willful misconduct. 
 9.3 Cadence Owned Equipment and Risk of Loss. All equipment supplied, owned or purchased by
Cadence as of the Effective Date is set forth in Exhibit F (“Cadence Owned Equipment”). All Cadence Owned Equipment shall at all times remain the property of Cadence and Cadence assumes the risk of loss
of such property. Cadence hereby waives any and all rights of recovery against Baxter, or against its directors, officers, employees, agents or representatives, for any loss or damage to Cadence Owned Equipment, to the extent the loss or damage is
covered or could be covered by insurance (whether or not such insurance is described in this Agreement), except if such loss or damage is caused by Baxter’s gross negligence or willful misconduct. Baxter will use Cadence Owned Equipment only
for activities directly related to development and commercialization of Product under this Agreement, except as otherwise agreed to in writing by Cadence. 

 

  
 17 

 CONFIDENTIAL 
  

 9.4 Maintenance-related Costs of Baxter Owned Equipment and Cadence Owned Equipment.
Baxter shall be responsible for maintaining the Cadence Owned Equipment consistent with its practices as in effect from time to time with respect to Baxter’s manufacturing equipment. Baxter shall be responsible for all maintenance-related
costs for Baxter Owned Equipment. Baxter shall be responsible for labor-related costs associated with the Routine Maintenance of Cadence Owned Equipment. For Cadence Owned Equipment, Cadence shall be responsible and reimburse Baxter for all costs
other than such labor-related Routine Maintenance costs, including without limitation, the costs associated with the purchase of spare parts, any labor-related costs incurred by a third party and costs associated with extraordinary maintenance so
long as such extraordinary maintenance is not caused by Baxter’s failure to provide adequate Routine Maintenance, or Baxter’s gross negligence or willful misconduct. 
 9.5 Performance Expectations for Cadence Owned Equipment. Within ninety (90) days after the Effective Date, Cadence and Baxter will mutually agree in writing on operating
specifications for the Specified Equipment. Baxter will not be deemed in breach of its obligation to deliver Product ordered under a Firm Purchase Order to the extent such non-delivery or delayed delivery is caused by the failure of the
Specified Equipment to perform in accordance with such operating specifications for the Specified Equipment (an “Equipment Failure Event”); provided, that such failure is not due to Baxter’s negligence or willful
misconduct, or any other cause within Baxter’s reasonable control; and provided, that Baxter (i) promptly notifies Cadence of the Equipment Failure Event as provided in Section 17.2, (ii) uses reasonable diligence and
efforts to remedy the situation if reasonably capable of being remedied by Baxter, (iii) continues performance of its obligations to the extent the Equipment Failure Event permits, and (iv) resumes performance of its obligations delayed by
the Equipment Failure Event as soon as possible.
  

	10.0	QUALITY MANAGEMENT 

10.1 Quality Agreement. The terms contained in the Quality Agreement are intended to complement the terms of this Agreement, and
they shall be interpreted as complementary to the extent possible. In the event of a conflict between the terms of the Quality Agreement and the terms of this Agreement, the terms of this Agreement shall control with respect to business, financial
and legal matters, and the terms of the Quality Agreement shall control with respect to quality control and quality assurance matters related to the Product (including, without limitation, manufacturing, testing, storage, release, change management
and validation activities); provided, however, that the inclusion of a particular term or level of detail in the Quality Agreement where such term or level of detail is absent from this Agreement shall not be deemed to constitute a conflict
between the two agreements. Only where competing terms in the two agreements conflict in terms of the principal focus of an express prescription or prohibition in the agreements shall a conflict between the two agreements be deemed to exist.

 10.2 Non-Compliance of Product. Cadence will be responsible for reviewing batch documentation for each batch of
Product and for providing Baxter with authorization to ship such Product batch. Cadence has the right to reject, at the expense of Baxter, Products that 

  
 18 

 CONFIDENTIAL 
  

 
deviate from the Product Specifications or Applicable Laws. Cadence or its designated agent shall review the batch documentation as set forth in the Quality Agreement and shall give Baxter
written notice (a “Deficiency Notice”) of all claims for Products that deviate from the Product Specifications or Applicable Laws within [***] ([***]) days after Cadence’s receipt of the final, Baxter-approved Batch Disposition
Certificate for the batch of Product in question (or, in the case of any defects not reasonably susceptible to discovery upon receipt of such final, Baxter-approved Batch Disposition Certificate, within [***] ([***]) days after discovery thereof by
Cadence, but in no event after the expiration date of the Product). Should Cadence fail to provide Baxter with the Deficiency Notice within the applicable [***] ([***])-day period, then the Product shall be deemed to have been accepted by Cadence on
the [***] day after Cadence’s receipt of the final, Baxter-approved Batch Disposition Certificate or discovery of the deficiency, as applicable. Except as set out in Section 15.2, Baxter shall have no liability for any deviations for which
Cadence has failed to provide notice within the applicable [***]-day period. Baxter shall use Commercially Reasonable Efforts to replace the non-compliant Product promptly. Any API consumed in producing non-compliant Product will be included in the
annual yield loss calculation as set forth in Section 8.4. 
 10.2.1 If Baxter and Cadence do not agree as to whether or
not the Product is non-compliant with the Product Specifications, then the Parties shall agree upon a specialized laboratory of recognized reputation for the purpose of determining the results. Any determination by such laboratory shall be final and
binding upon the Parties hereto. 
 10.2.21 If Baxter and Cadence do not agree as to whether or not the Product is non-compliant
with Applicable Laws, then the dispute shall be resolved in accordance with Section 16.0 of this Agreement (“Alternative Dispute Resolution”), provided, however, that if the Parties agree that such dispute would more
appropriately be resolved in accordance with the procedure set forth in Section 10.2.1, then that procedure will be used, instead. 
 10.2.3 If the Product is confirmed to be non-compliant with the Product Specifications, in accordance with Section 10.2.1, or Applicable Laws, in accordance with Section 10.2.2, as applicable,
Baxter shall pay all costs associated with such analysis, and Cadence shall not be required to pay the Manufacturing Fee for such Product. If Product is confirmed to be compliant, Cadence shall pay all costs associated with such analysis, in
addition to paying the Manufacturing Fee for such Product. 
 10.3 Product Recalls. Cadence shall determine if a Product
recall or marketing withdrawal is required, and shall be responsible for the conduct of any such recall or marketing withdrawal; provided, however, that Baxter shall reasonably cooperate with any such action. If a Product recall
results from the gross negligence or intentional misconduct of Baxter, Baxter will promptly replace the Product and reimburse Cadence for the actual costs associated with any recall or marketing withdrawal of the Product. Following Baxter’s
notice to Cadence that additional API will be required to replace defective Product, Cadence will promptly provide to Baxter API necessary for replacement of such Product. Cadence will provide to Baxter 

 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 19 

 CONFIDENTIAL 
  

 
appropriate documentation evidencing the actual replacement cost of the API paid by Cadence to its supplier including duty, freight and testing costs. Notwithstanding the foregoing, Baxter will
pay no more for the additional API than Cadence’s actual costs for the replacement API, plus duty, freight and testing costs. 
 10.4 Product Complaints. Product Complaints shall be handled in accordance with the Quality Agreement. In general, Baxter shall promptly notify Cadence of any and all complaints of which Baxter
becomes aware relating to any Product, and shall forward to Cadence’s designated quality representative or such other individual as Cadence shall designate a copy of any such written complaint received by Baxter. Cadence shall promptly inform
Baxter of any and all complaints that Cadence receives which implicate Baxter’s manufacturing or other processes at the Facility. Notification shall be given by telephone, with a facsimile confirmation immediately following. 

10.5 Adverse Events (“AE”). Adverse Events shall be handled in accordance with the Quality Agreement. With respect to
any Product, Baxter shall notify Cadence in accordance with the timeline set forth in the Quality Agreement following Baxter’s receipt of written information of an Adverse Event. To the extent an Adverse Event of which Cadence becomes aware
implicates Baxter’s manufacturing or other processes at the Facility, Cadence shall inform Baxter in accordance with the timeline set forth in the Quality Agreement of such Adverse Event and shall disclose to Baxter any information it has
regarding that Adverse Event. 
 10.6 Retained Samples. Baxter shall retain samples from each batch of Products in
accordance with the Quality Agreement. 
 10.7 Changes to Product Specifications. The Product Specifications may not be
amended, changed or supplemented by Baxter without the prior written consent of Cadence. Cadence will give Baxter not less than ninety (90) days advanced written notice of an intention to implement voluntary changes in Product Specifications
initiated by Cadence so that the Parties can collaborate on a plan to implement any related changes required to meet such changed Product Specifications in a timely and cost-efficient manner. For Product Specification changes mandated by Regulating
Groups, Baxter shall use Commercially Reasonable Efforts to expedite such changes upon the request of Cadence. The allocation of the cost of manufacturing and Facility changes required as a result of a change in Product Specifications will be
determined by agreement of the Parties on a case-by-case basis as provided in Section 7.4. Baxter will provide Cadence with all information needed to amend the NDA for the Product and other Regulatory Submissions as a result of any approved
Product Specification change. Baxter will continue to supply Cadence with Product approved under Cadence’s NDA for the Product and other Regulatory Submissions until such time as the changed Product Specifications are permitted by each of the
applicable Regulating Groups, except as the Parties otherwise agree by separate written agreement. 

  
 20 

 CONFIDENTIAL 
  

 10.8 Changes to Drug Product Manufacturing Process. Changes to the Drug Product
Manufacturing Process (as defined below) will ultimately be governed by the Quality Agreement. Baxter will discuss any proposed changes to the Drug Product Manufacturing Process with Cadence and obtain approval for any associated change control plan
prior to implementation of any development work to qualify the change. Baxter will follow its established procedures for changes which are made to its manufacturing process from Product mix to release and which relate to the manufacture of the
Product (“Drug Product Manufacturing Process”). Baxter will notify Cadence of all such changes/revisions that require notice based on the Quality Agreement and Regulatory Documentation as provided to Baxter or such changes/revisions
that could reasonably be expected to have a material effect on the Product. Baxter will obtain Cadence’s written approval prior to making any such change or revision. Any such changes in the Drug Product Manufacturing Process will be done at
Baxter’s expense. Baxter will provide Cadence with all information needed to review and approve any changes and that are necessary to amend the NDA for the Product and other Regulatory Submissions as a result of any approved Drug Product
Manufacturing Process change. Baxter will continue to supply Cadence with Product approved under Cadence’s NDA for the Product and other Regulatory Submissions until such time as the Product manufactured under the changed process is permitted
by each of the applicable Regulating Groups, except as the Parties otherwise agree by separate written agreement. Notwithstanding the foregoing, in the event any changes to the Drug Product Manufacturing Process are requested by Cadence, Baxter
shall review the requested changes and Cadence shall obtain Baxter’s written approval, prior to the implementation of any such changes. The costs associated with any changes to the Drug Product Manufacturing Process requested by Cadence shall
be the responsibility of Cadence. All costs associated with any other changes to the Drug Product Manufacturing Process shall be mutually determined by the Parties. 
  

	11.0	MARKETING 

 11.1
General. The Parties will cooperate in a reasonable manner to support and facilitate the sale of the Product in the Territory and communicate regularly to facilitate carrying out their respective responsibilities. 

 

	12.0	REPRESENTATIONS AND WARRANTIES 

 12.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party that, as of the Effective Date (i) this Agreement is legal and valid and the
obligations binding upon such Party are enforceable in accordance with their terms, subject to bankruptcy, insolvency, moratorium, reorganization or similar laws affecting the rights of creditors generally and the availability of equitable remedies,
(ii) the execution, delivery and performance of this Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such Party may be bound, nor violate any law or regulation of any court, governmental
body or administrative or other agency within the Territory having jurisdiction over it, and (iii) the Party owns, controls, or has the right to grant to 

  
 21 

 CONFIDENTIAL 
  

 
the other Party the licenses and other rights to use the intellectual property it authorizes the other Party to use in carrying out the objectives of this Agreement and the Party is not aware of
any restrictions, limitations or interests superior to the Party’s intellectual property rights which would prevent the other Party from using such intellectual property in carrying out the objectives of this Agreement or which would cause the
other Party to infringe the rights of others. During the Term of the Agreement, if a Party becomes aware of any events or circumstances that are reasonably likely to cause its representations and warranties to be untrue, the Party will promptly
provide the other Party with written notice of such events or circumstances, including details reasonably requested by the other Party in order to evaluate the impact of such events or circumstances on this Agreement. 

 

	 	12.2	Warranties of Cadence. 

12.2.1 API. Cadence represents, warrants and covenants that the API, when delivered to Baxter hereunder, will, to the best of its
knowledge after due inquiry (i) be manufactured, tested, and packaged in accordance with applicable cGMP regulations and all applicable laws and regulations of the FDA and other applicable Regulating Groups; (ii) meet the API
Specifications; (iii) not be adulterated or misbranded within the meaning of the FD&C Act or any similar laws or regulations of applicable Regulating Groups; and (iv) not be an article which may not be introduced into interstate
commerce under the FD&C Act or any similar laws or regulations of applicable Regulating Groups. 
  

	 	12.2.2 	Replacement. 

12.2.2.1 In the event of non-acceptance by Baxter of any delivery of API due to its failure upon inspection or testing by Baxter
to meet Cadence’s warranties set forth in Section 12.2.1, Cadence’s sole obligation and Baxter’s exclusive remedy will be limited to replacement of the API (subject to the provisions of this Section). 

12.2.2.2 If, however, the failure of API to meet Cadence’s warranties is not discoverable upon reasonable physical
inspection and testing, but is identified by Baxter after storage and handling by Baxter in accordance with the Product labeling, then Cadence’s obligation will also include payment to Baxter of the Manufacturing Fee per unit of Product
required to be replaced using non-defective API. 
 12.2.2.3 Following notice from Baxter and at the direction of
Cadence, Baxter will return the then remaining defective API or Product that incorporates defective API or is otherwise non-compliant to Cadence or, at Baxter’s option or if requested by Cadence, destroy the same or deliver it to a third party
qualified in such waste disposal. Cadence will bear the cost of any return of API, Product or work-in-process, including freight and handling, and the costs of API, Product and/or work-in-process destruction, if requested by Cadence. Cadence will,
at its expense, replace defective API as expeditiously as possible and pay Baxter for Product and work-in-process incorporating defective API within thirty (30) days of receipt of Baxter’s detailed invoice following completion of the
designated return or destruction hereunder. 

  
 22 

 CONFIDENTIAL 
  

	 	12.3	Warranties of Baxter. 

12.3.1 General. Baxter represents, warrants and covenants that Product manufactured under this Agreement, at the time of release at
the Facility (i) will be manufactured, tested, and packaged in accordance with this Agreement, the Quality Agreement, applicable cGMP regulations and all other applicable laws and regulations of the FDA and other applicable Regulating Groups;
(ii) will meet the Product Specifications; (iii) will not be adulterated or misbranded within the meaning of the FD&C Act or any similar laws or regulations of applicable Regulating Groups; and (iv) will not be an article which
may not be introduced into interstate commerce under the FD&C Act or any similar laws or regulations of applicable Regulating Groups. Notwithstanding the foregoing, this warranty will not extend to the API or the Formulation, nor to Product
labeling, and will not apply to the extent Cadence has breached its warranty under Section 12.2.1. 
 12.3.2
Facility. At all times during the Term of the Agreement, Baxter shall (i) perform Baxter’s obligations under this Agreement in compliance with all Applicable Laws; (ii) use Commercially Reasonable Efforts to protect and maintain
the Cadence Owned Equipment; and (iii) maintain sufficient expertise, with respect to personnel and equipment, to fulfill the obligations of Baxter established hereunder. 
 12.3.3 Product. Baxter represents, warrants and covenants that (i) Baxter or its Affiliate shall transfer to Cadence good and marketable title to the Products free from any and all liens,
mortgages or encumbrances of any kind; (ii) all Product manufactured and supplied to Cadence under this Agreement shall have a shelf life of no less than [***]; and (iii) Baxter shall use Commercially Reasonable Efforts to supply Product
under this Agreement with a shelf life of no less than [***]. Such shelf life shall be measured against the month of expiration that is imprinted on the label at the time of manufacture. Baxter further represents, warrants and covenants that all
batches of the Product shall be made available by Baxter for pick-up by Cadence or its designee promptly. For purposes of this Section 12.3.3, “date of its release” shall mean the date the Product is approved by Baxter quality control
as evidenced by the issuance of a certificate of compliance. 
 12.3.4 Debarred Persons. Baxter covenants that it will
not in the performance of its obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C. §335(a) or (b). 
 12.3.5 Cadence Licensed Intellectual Property. Baxter acknowledges and agrees that (A) it has been informed that Product is to be made subject to the Cadence Licensed Intellectual Property,
and (B) that it will only manufacture Product for the benefit of Cadence and its sublicensees. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 23 

 CONFIDENTIAL 
  

 12.3.6 Replacement. Baxter’s sole obligation and Cadence’s exclusive
remedy for breach of Baxter’s warranties set forth in Sections 12.3.1 through 12.3.4, other than if such breach is caused by the gross negligence or intentional misconduct of Baxter, will be limited to replacement of the Product and including
reimbursement of Cadence’s actual costs associated with any recall or marketing withdrawal of the Product. Following Baxter’s notice to Cadence that additional API will be required to replace defective Product, Cadence will promptly
provide to Baxter API necessary for replacement of such Product. Cadence will provide to Baxter appropriate documentation evidencing the actual replacement cost of the API paid by Cadence to its supplier including duty, freight and testing costs.
Any API consumed in producing defective Product will be included in the annual yield loss calculation as set forth in Section 8.4. Notwithstanding the foregoing, Baxter will pay no more for the additional API than Cadence’s actual costs
for the replacement API, plus duty, freight and testing costs. 
 12.4 Limitation of Warranties. NEITHER PARTY MAKES ANY
OTHER EXPRESSED OR IMPLIED WARRANTY EXISTS, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND EACH PARTY EXPRESSLY DISCLAIMS ANY SUCH WARRANTIES. Except as provided in Article 15.0, or as otherwise expressly stated
in this Agreement, neither Party will be liable to the other Party for any proximate, indirect, incidental or consequential damages arising from a breach of warranty under this Agreement. 

 

	13.0	CONFIDENTIALITY 

 13.1
Preexisting Confidentiality Agreement. The Parties have previously signed a Confidential Disclosure Agreement effective April 6, 2006, a copy of which is attached to this Agreement as Exhibit G, to cover the exchange of confidential
information and materials relating to [***]. 
 13.2 Confidentiality. Any Confidential Information of the Parties
exchanged hereunder shall be governed by, and shall be maintained in confidence pursuant to, the confidentiality provisions set forth in the Confidential Disclosure Agreement. 
 13.3 Exceptions. In addition to the exceptions set forth in the Confidential Disclosure Agreement, Cadence may provide a copy of this Agreement and all its exhibits and amendments to the licensors
of the Cadence Licensed Intellectual Property, Bristol-Myers Squibb Company and SCR Pharmatop; provided, however, that Cadence will redact all terms related to confidential financial information, and shall request of such licensors of
the Cadence Licensed Intellectual Property the ability to redact other terms as reasonably requested to be redacted by Baxter prior to providing such documents to licensors of the Cadence Licensed Intellectual Property. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 24 

 CONFIDENTIAL 
  

 13.4 Publicity and SEC Filings. Except as set forth in Sections 13.4.1 or 13.4.2
or unless the prior written consent of the other Party is obtained, no Party shall, except as may be required by law or regulation, in any manner disclose or advertise or publish or release for publication any statement mentioning the other Party or
information contained in or acquired pursuant to this Agreement, or the fact that any Party has furnished or contracted to furnish the other Party the items required by this Agreement, or quote the opinion of any employee of the other Party. No such
notice shall be required and each Party may disclose any previously disclosed information if the substance of the description of or reference to this Agreement contained in the proposed filing or disclosure has been included in any previous filing
made by either Party hereunder or otherwise approved by the other Party. Either Party may communicate to its investors information to the extent made public by the other Party. 

13.4.1 Press Releases. The Parties agree that any press release or other public announcement of the execution of this Agreement
(except for filings included under Section 13.4.2) shall only be by one or more press releases mutually agreed to by the Parties. The failure of a Party to return a draft of a press release with its proposed amendments or modifications to such
press release to the other Party within three (3) business days of such Party’s receipt of such press release shall be deemed as such Party’s approval of such press release as received by such Party. 

13.4.2 SEC Filings. In the event that Cadence is advised by counsel to file with the Securities and Exchange Commission or the
securities regulators of any state or other jurisdiction, a registration statement or other disclosure document which describes or refers to this Agreement under the Securities Act of 1933, as amended, the Exchange Act, or any other Applicable Law
relating to securities matters, Cadence shall notify Baxter of such intention and shall provide Baxter with a copy of relevant portions of the proposed filing not less than three (3) business days prior to such filing (and any revisions to such
portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto relating to this Agreement, and shall use reasonable efforts to obtain confidential treatment of any information concerning this Agreement
that Baxter requests be kept confidential, and shall only disclose Confidential Information which it is advised by counsel or the Securities and Exchange Commission is legally required to be disclosed. 

13.5 Survival. The obligations under this Article 13 will extend for the longer of the Term of the Agreement or [***]. 

 

	14.0	INTELLECTUAL PROPERTY 

  

	 	14.1	Ownership of Inventions. 

14.1.1 Ownership of Background Intellectual Property Rights. Ownership of Background Intellectual Property Rights will remain in
the Party owning them on the Effective Date of the Original Agreement. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 25 

 CONFIDENTIAL 
  

 14.1.2 Cadence Ownership. The entire right, title and interest in all
discoveries, inventions and improvements which are conceived or reduced to practice during the course of the work being performed pursuant to this Agreement (i) solely by Cadence or its employees, agents or other representatives; or
(ii) by Baxter or its employees, agents or other representatives (alone or jointly with one or more Cadence employees, agents or representatives) useful only in connection with the Compound, the Product and/or the Formulation (the
“Cadence Inventions”) will be owned solely by Cadence. 
 14.1.3 Baxter Ownership. The entire right,
title and interest in all discoveries, inventions and improvements which are conceived or reduced to practice during the course of work being performed pursuant to this Agreement solely by Baxter or its employees, agents or other representatives,
other than Cadence Inventions and Joint Inventions (the “Baxter Inventions”) will be owned solely by Baxter, subject to Sections 14.2.2 and 14.3. 
 14.1.4 Joint Ownership. Subject to Sections 14.1.2 and 14.1.3, the entire right, title and interest in all discoveries, inventions and improvements which are conceived or reduced to practice during
the course of the work being performed pursuant to this Agreement jointly by (i) Cadence or its employees, agents or other representatives and (ii) Baxter or its employees, agents or other representatives (the “Joint
Inventions”) will be jointly owned by Cadence and Baxter, each of which will own an undivided one-half (1/2) interest in such invention, subject to Sections 14.2.2 and 14.3. Each Party will cooperate with the other in completing any
Patent Applications relating to Joint Inventions, and in executing and delivering any instrument required to assign, convey or transfer to each Party its undivided one-half (1/2) interest. 

14.1.5 Assignment of Ownership Rights. All employees, consultants, subcontractors and agents performing services for a Party under
this Agreement shall have assigned in writing to such Party all of their right, title and interest in, to and under any and all discoveries, inventions and improvements directly related to the Product so as to effectuate the provisions of this
Article 14. 
  

	 	14.2	Reports: Information Developed During Development Plans. 

 14.2.1 Content of Reports. Baxter will provide to Cadence reports containing the data, test results, and specifications or procedures for the Product developed specifically for the Compound and/or
the Formulation (“API/Formulation Specifications”), as described in any Development Plan, which, collectively with the Baxter Development Deliverables, shall be referred to herein as the “Reports.” The
Reports may also contain references to (i) Baxter standard operating procedures, specifications, material codes and their specifications, and other information developed by Baxter prior to the Original Effective Date, but not including any such
procedures, specifications, material codes and their specifications or other information developed by Baxter in its Grosotto facility and which is owned or licensed to the licensor of Cadence Licensed Intellectual Property (“Preexisting
Specifications”) that fall within Baxter Background 

  
 26 

 CONFIDENTIAL 
  

 
Intellectual Property Rights and (ii) original laboratory notebooks and other Good Laboratory Practices documentation generated by Baxter or its agents pursuant to this Agreement or the
Original Agreement (“Original Product Data”). 
 14.2.2 Ownership of Reports and Contents. The Reports,
the Original Product Data solely as it relates to the Product, and the data, test results, and API/Formulation Specifications therein, will become the property of Cadence and will be treated as Cadence’s Confidential Information and be subject
to the provisions of Article 13.0 of this Agreement. For the avoidance of doubt, the Reports, data, test results and API/Formulation Specifications will become the property of Cadence even if they constitute Baxter Inventions under
Section 14.1.3 or Joint Inventions under Section 14.1.4, subject to the Cadence Product License granted to Baxter under Section 14.3.1. Preexisting Specifications, Baxter Background Intellectual Property Rights, as well as Original
Product Data (other than as it relates to the Product), will remain the property of Baxter and will constitute Baxter’s Confidential Information and be subject to the provisions of Article 13.0 of this Agreement, subject to the Baxter License
under Section 14.3.2. 
 14.2.3 Archiving of Reports. Baxter will retain the original Reports and Original Product
Data for archival purposes. 
  

	 	14.3	Licenses. 

 14.3.1 To
Baxter From Cadence. Cadence hereby grants to Baxter a nonexclusive, royalty-free license, with a right to sublicense solely to a Baxter Affiliate, to make the Product in the Territory under Cadence Background Intellectual Property Rights,
Cadence Licensed Intellectual Property, Cadence Inventions and Joint Inventions (the “Cadence Product License”), only to the extent necessary for Baxter to fulfill Baxter’s obligations under this Agreement. The Cadence Product
License shall be subject and subordinate to the IV APAP Agreement and the Pharmatop License Agreement. BMS shall be an express third party beneficiary of Baxter’s obligations under the Cadence Product License that relate to compliance with the
terms and conditions of the IV APAP Agreement with the express right to enforce the same directly against Baxter. Cadence shall provide Baxter with the text of any amendment or restatement of either the IV APAP Agreement or the Pharmatop License
Agreement within fourteen (14) days after the effective date of such amendment or restatement; provided, however, that Cadence may redact the text to delete confidential information solely to the extent such confidential
information does not alter the scope of either Party’s rights under this Agreement. The Cadence Product License shall terminate immediately upon the termination of the sublicense or license from BMS to Cadence with respect to such right, but
Cadence must provide prompt notice of such termination to Baxter. Cadence shall indemnify Baxter against any claim of infringement, misappropriation or unauthorized use of Cadence Licensed Intellectual Property to the extent such claim arises from
Baxter’s use of Cadence Licensed Intellectual Property after termination of the Cadence Product License but before Baxter received actual notice of such termination. 

  
 27 

 CONFIDENTIAL 
  

 14.3.2 To Cadence From Baxter. Baxter hereby grants to Cadence (a) a
nonexclusive, royalty-free, license in the Territory, with a right to sublicense to Cadence Affiliates, licensors of Cadence Licensed Intellectual Property and, with Baxter’s prior written consent, not to be unreasonably withheld, conditioned
or delayed, Cadence sublicensees, to make, have made, use, sell, offer for sell and import the Product under Baxter Background Intellectual Property, only to the extent that such Baxter Background Intellectual Property is actually used in the
manufacture of the Product under this Agreement; and (b) an exclusive, royalty-free, worldwide license, with a right to sublicense to Cadence Affiliates, licensors of Cadence Licensed Intellectual Property and, with Baxter’s prior written
consent, not to be unreasonably withheld, conditioned or delayed, Cadence sublicensees, to make, have made, use, sell, offer for sale and import the Product under all Baxter Inventions and Baxter’s interest in all Joint Inventions, each only to
the extent actually used in connection with the Compound, the Product and/or the Formulation (collectively (a) and (b) of this Section 14.3.2 shall be known as the “Baxter License”). The license set forth in
subsection (b) of the immediately preceding sentence shall be exclusive, even as to Baxter, only to the extent such Baxter Inventions and Joint Inventions are actually used in connection with the Compound, the Product and/or the Formulation.
Baxter shall retain full rights to exploit such Baxter Inventions and Joint Inventions (i) for the purpose of performing its obligations under this Agreement and (ii) to the extent such Baxter Inventions and Joint Inventions are not used
in connection with the Compound, the Product and/or the Formulation. The license set forth in subsection (b) hereof shall become nonexclusive, and all sublicenses under the Baxter License (except for sublicenses to Cadence Affiliates and
licensors of Cadence Licensed Intellectual Property) shall terminate, immediately upon the termination of this Agreement, the IV APAP Agreement or the Pharmatop License Agreement. Notwithstanding the foregoing, the Baxter License shall survive if
this Agreement is terminated by Cadence pursuant to Sections 19.2.1.1 or 19.2.1.2. 
 14.3.3 Pre-Existing Specifications and
Original Product Data. Baxter will (i) make Preexisting Specifications referenced in the Reports and Original Product Data available to Regulating Groups as directed by such Regulating Groups and as provided in Article 5.0, (ii) upon
Cadence’s reasonable request, provide copies of Preexisting Specifications referenced in the Reports and relevant portions of Original Product Data (but excluding data or information which is unrelated to the Product) to Cadence for
Cadence’s use in Regulatory Submissions outside the United States if (a) pursuant to Article 5.0 such information is reasonably required for Cadence’s Regulatory Submission for the Product in the Territory and (b) Cadence agrees
to treat all such information (other than as it relates to the Product and which is owned by Cadence under this Agreement) as Baxter’s Confidential Information under the provisions of Article 13.0. 

 

	 	14.4	Patents. 

 14.4.1
Patent Filings on Solely-Owned Inventions. Each Party will, in its sole discretion, prepare, file, prosecute and maintain Patent Applications for inventions as to which it has sole ownership under Sections 14.1.2 and 14.1.3 above and will be
responsible for related 

  
 28 

 CONFIDENTIAL 
  

 
interference proceedings. Each Party will endeavor to ensure whenever possible that claims are filed and prosecuted in such Patent Applications specifically directed to the Field. At least thirty
(30) days prior to the contemplated filing date, each Party responsible for preparing a Patent Application will submit to the other Party a substantially completed draft of such Patent Application. Each Party will bear all costs under this
Section for inventions as to which it has sole ownership. Each Party will cooperate with the other Party’s perfection of filings. 
 14.4.2 Joint Inventions and Patent Filings. With respect to all Patent Applications on Joint Inventions (“Joint Patent Applications”), Baxter will prepare and file Joint Patent
Applications and will diligently prosecute and maintain same. At least thirty (30) days prior to the contemplated filing, Baxter will submit a substantially completed draft of all such Joint Patent Applications to Cadence for its approval. As
to claims contained in any Joint Patent Application directed to the Field, Cadence shall have the right to comment and to have any such reasonable comments incorporated into the claims included in such Joint Patent Application prior to filing. If
the Parties are unable to resolve any differences regarding the claim language directed to the Field, the matter will be handled pursuant to Section 16.0 of this Agreement. As to claims contained in any Joint Patent Applications directed
outside the Field, Baxter will confer with Cadence and shall in good faith consider adopting Cadence’s suggestions regarding the prosecution of such claims included in the Joint Patent Applications after taking into account the interests of
Cadence and its licensors and sublicensees under the Joint Patent Applications. The Parties will share equally the costs of the preparation, filing, prosecution and maintenance of any Joint Patent Applications and will share equally the costs of any
related interference proceedings. Baxter will copy Cadence with any official actions and submissions in such Joint Patent Applications. If either Party elects not to pay its portion of any shared costs for a Joint Patent Application, the other Party
may proceed with such Joint Patent Application in its own name and at its sole expense, in which case the Party electing not to pay its share of costs will assign its entire right, title and interest in and to such Joint Patent Application to the
other Party. Any such election and related assignment shall be on a jurisdiction-by-jurisdiction basis. 
 14.4.3 Public
Disclosure. Each Party agrees to delay any public disclosure of the subject matter of any Patent Application until after filing of such Patent Application, but in no event less than one hundred eighty (180) days after notice to the other
Party of the intent to disclose such subject matter. 
  

	15.0	INDEMNIFICATION 

 15.1
Indemnification By Cadence. Cadence, on its own behalf, and on behalf of its Affiliates, will defend, indemnify and hold harmless Baxter and its Affiliates, and their respective directors, officers, shareholders, employees and agents, and each
of their successors and permitted assigns, from and against any and all third party claims, actions, causes of action, liabilities, losses, damages, costs or expenses, and resulting settlements, awards or judgments, including reasonable
attorneys’ fees (“Damages”), which arise out of or relate to (i) the failure of API provided by Cadence hereunder to meet the warranties set forth in Section 12.2.1; (ii) a

  
 29 

 
breach by Cadence of any of its other representations, warranties, covenants, agreements or obligations under this Agreement; (iii) the negligence or willful misconduct of Cadence in the
performance or nonperformance of any of Cadence’s obligations under this Agreement; (iv) personal injury or property damage caused by the Product at any time before or after first commercial sale (except to the extent covered by
Baxter’s indemnification obligations set forth in Section 15.2); or (v) any Patent, trade name, trademark, service mark or copyright infringement, or any claim or judgment of such infringement thereof, relating to the Formulation or
API supplied by Cadence, or to the Product (except to the extent covered by Baxter’s indemnification obligations pursuant to Section 15.2), or the intellectual property licensed to Baxter under Section 14.3.1, or the use or printing
of any trademark(s), trade names or copyrightable materials of Cadence or its Affiliates, as authorized by this Agreement. 

15.2 Indemnification By Baxter. Baxter, on its own behalf, and on behalf of its Affiliates, will defend, indemnify and hold
harmless Cadence and its Affiliates, and their respective directors, officers, shareholders, employees and agents, and each of their successors and permitted assigns, from and against any and all Damages which arise out of or relate to (i) the
failure of Product provided by Baxter hereunder to meet the warranties set forth in Section 12.3; (ii) a breach by Baxter of any of its other representations, warranties, covenants, agreements or obligations under this Agreement;
(iii) the negligence or willful misconduct of Baxter in manufacturing Product or in the performance or nonperformance of any of Baxter’s obligations under this Agreement; or (iv) any Patent, trade name, trademark, service mark or
copyright infringement, or any claim or judgment of such infringement thereof, relating to the manufacturing processes or equipment used by Baxter to manufacture the Product (excluding the Cadence Owned Equipment and further except to the extent
covered by Cadence’s indemnification obligations pursuant to Section 15.1), or the intellectual property licensed to Cadence under Section 14.3.2, or the use of any trademark(s), trade names or copyrightable materials of Baxter or its
Affiliates, as authorized by this Agreement. 
 15.3 Notice; Procedure. The indemnified Party will give the indemnifying
Party prompt written notice of any claim, proceeding or suit for which it seeks indemnification under Sections 15.1 or 15.2 (hereafter, a “Matter”). The indemnifying Party will have fifteen (15) business days after receipt of
the indemnified Party’s notice to notify the indemnified Party that the indemnifying Party elects to conduct and control the defense of such Matter. If the indemnifying Party does not give the foregoing notice, the indemnified Party will have
the right to defend or settle such Matter in the exercise of its exclusive discretion, and the indemnifying Party will, upon request from the indemnified Party, promptly pay to it in accordance with Sections 15.1 or 15.2, as the case may be, the
amount of any Damages resulting from such Matter. Except in the event of a conflict of interest between the indemnified Party and the indemnifying Party, if the indemnifying Party gives the foregoing notice, the indemnifying Party will have
the obligation to undertake, conduct and control, through counsel of its own choosing and at the sole expense of the indemnifying Party, the conduct and control of the defense and any settlement of such Matter and the indemnified Party will
cooperate with the indemnifying Party in connection therewith; provided, that: (a) the indemnifying Party will not thereby permit any 

  
 30 

 CONFIDENTIAL 
  

 
lien, encumbrance or other adverse charge upon any asset of the indemnified Party; (b) the indemnifying Party will permit the indemnified Party to participate in the defense or settlement
through counsel chosen by the indemnified Party, but the fees and expenses of such counsel will be borne by the indemnified Party except as provided in clause (c) below; (c) the indemnifying Party will agree to reimburse promptly under
Sections 15.1 or 15.2, as the case may be, the indemnified Party for the full amount of any liabilities, losses, damages, costs and expenses, including reasonable attorney” fees, resulting from the Matter, except for any fees and expenses of
counsel for such indemnified Party incurred after the assumption of the conduct and control of such Matter by the indemnifying Party; and (d) the indemnifying Party will not settle or otherwise resolve any Matter without prior notice to the
indemnified Party and the consent of the indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). So long as the indemnifying Party is contesting any Matter in good faith, the indemnified Party will not pay or
settle any such Matter; except that such indemnified Party will have the right to pay or settle any such Matter but in so doing such indemnified Party will be deemed to have waived any right to indemnity therefore by the indemnifying Party under
Section 15.1 or 15.2, as the case may be. 
 In the event that the indemnified Party reasonably believes that there exists
a substantial conflict of interest with the indemnifying Party, then the indemnified Party will give the indemnifying Party notice of such conflict of interest and the indemnifying Party will not have the right or obligation to undertake, conduct
and control the defense or settlement of any Matter and the indemnified Party will have the right to defend or settle such Matter in the exercise of its exclusive discretion; provided, that the indemnifying Party (a) will not thereby
permit any lien, encumbrance or other adverse charge upon any asset of the indemnified Party; and (b) will not settle or otherwise resolve any Matter without prior notice to the indemnified Party and the consent of the indemnified Party (which
consent shall not be unreasonably withheld, conditioned or delayed). In such event, the indemnifying Party will, upon request from the indemnified Party, promptly pay to it in accordance with Section 15.1 or 15.2, as the case may be, the amount
of any liabilities, losses, damages and expenses, including reasonable attorneys’ fees, resulting from such claim, proceeding or suit. 
 15.4 No Claim for Losses. In no event will either Party or their respective Affiliates be liable for any special, indirect, incidental or consequential damages arising out of this Agreement.

 15.5 Insurance. Baxter is self-insured for the types of liabilities for which indemnification by Baxter is likely to
arise under Section 15.2. Prior to commercial launch of the Product, Cadence will obtain and keep in force at its sole expense during the Term of the Agreement, the following insurance covering Cadence and its agents, employees, representatives
and subcontractors: (i) Comprehensive or Commercial General Liability in an amount not less than [***] dollars ($[***]) each occurrence combined single limit for bodily injury and property damage for products completed operations (including
vendors coverage), blanket contractual liability, personal injury and independent contractors protective insurance, which name Baxter as an additional insured and require at least thirty (30) days written notice to Baxter prior to any
cancellation, non-renewal or material change in coverage. Cadence will provide Baxter with a certificate of insurance evidencing compliance with this insurance obligation. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 31 

 CONFIDENTIAL 
  

	16.0	ALTERNATE DISPUTE RESOLUTION 

 The Parties will attempt to settle any claim or controversy arising out of this Agreement through good faith negotiations and in the spirit of mutual cooperation. Any issues that cannot be resolved by the
Senior Executives as set forth in Section 3.2 or any other issues between the Parties will be referred to the Chief Executive Officer of Cadence and the General Manager of Baxter’s BioPharma Solutions business (the “Executive
Officers”) to resolve the dispute. In the event such Executive Officers cannot resolve the dispute, the dispute will be mediated by a mutually acceptable mediator to be chosen by the Parties within thirty (30) days after written notice
by the Party demanding mediation. Neither Party may unreasonably withhold consent of the selection of the mediator and the Parties will share the costs of the mediation equally. The Parties may agree to replace mediation with some other form of
Alternative Dispute Resolution “ADR”), such as neutral fact-finding or a mini-trial. Any dispute which cannot be resolved by the Parties through mediation or another form of ADR within ninety (90) days of the date of the
initial written demand for mediation may then, and only then, be submitted to the Federal or state courts, as appropriate, for resolution. Nothing in this Section will prevent either Party from resorting to judicial process if (i) good faith
efforts to resolve the dispute under these procedures have been unsuccessful or (ii) injunctive relief from a court is necessary to prevent serious and irreparable injury to one Party or to others. 

 

	17.0	FORCE MAJEURE 

 17.1
General. Neither Party will be liable, or deemed in breach of its obligations under this Agreement, for a delay in performance or nonperformance as the result of an act of governmental authority, war, acts of terrorism, riot, fire, explosion,
hurricane, flood, strike, lockout, or injunction; inability to obtain fuel, power, raw Materials, labor, containers, plastic film or components, or transportation facilities; accident, breakage of machinery or apparatus solely to the extent not
caused by such Party’s negligence or willful misconduct; or any other cause beyond its reasonable control preventing the manufacture, shipment, or acceptance, of the Product, or any component thereof (“Force Majeure”),
provided, that the affected Party (i) promptly notifies the other Party of the Force Majeure event as provided in Section 17.2, (ii) uses reasonable diligence and efforts to remedy the situation if reasonably capable of being
remedied by that Party, (iii) continues performance of its obligations to the extent the Force Majeure event permits, and (iv) resumes performance of its obligations delayed by Force Majeure events as soon as possible. This requirement
that any Force Majeure be remedied with all reasonable dispatch will not require settlement of strikes or labor controversies by acceding to the demands of the opposing parties in such strikes or labor controversies. 

  
 32 

 CONFIDENTIAL 
  

 17.2 Notice. A Party affected by Force Majeure will promptly notify the other
explaining the nature, details, and expected duration thereof. The affected Party will advise the other Party from time to time as to progress in remedying the situation and as to the time when the affected Party expects to resume its obligations
and will notify the other Party as to the expiration of any Force Majeure as soon as the affected Party knows the date thereof. If a Party anticipates that a Force Majeure is reasonably likely to occur, that Party will notify the other Party as soon
as practicable, explaining the nature, details, and expected duration thereof. 
  

	18.0	RELATIONSHIP OF THE PARTIES 

 It is expressly acknowledged and agreed that Baxter and Cadence will be independent contractors and that the relationship between the two Parties will not constitute a partnership, joint venture or
agency. Neither Party, nor its agents or employees, will be deemed agents or representatives of the other Party. Neither Party will have the right to enter into any contracts or commitments in the name of or on behalf of the other Party, without the
prior written consent of the other Party to do so. Nothing herein will be construed as granting any license or right under any Patent or trademark right of either Party, by implication or otherwise, to the other except as expressly provided herein.

  

	19.0	TERM AND TERMINATION 

19.1 Term and Expiration. This Agreement will be effective as of the Effective Date and will terminate on November 1, 2015
(“Initial Term”), unless terminated earlier as herein provided or extended as provided in Section 19.1.2 (“Term of the Agreement”). 
 19.1.2 Automatic Renewal. Upon expiration of the Initial Term, this Agreement will automatically renew thereafter for consecutive one (1) year terms on each successive annual anniversary of
the Contract Year unless either Party, by not less than two (2) years prior written notice to the other Party, signifies by such notice its intention to terminate this Agreement upon the expiration of the applicable Contract Year. By way of
clarification, if either Party desires that this Agreement terminate at the end of the Initial Term, the Party must give written notice before the first day of the fourth Contract Year. 

 

	 	19.2	Early Termination 

19.2.1 Termination by Either Party. Either Party may terminate this Agreement as follows: 

19.2.1.1 effective ninety (90) days after written notice given by the non-breaching Party of a material breach of this
Agreement by the other Party, if such breach is not cured within ninety (90) days of receipt of such notice containing details of such breach (or such additional time as is reasonably necessary to cure such breach, provided, the
breaching Party has commenced a cure within the ninety (90) day period and is diligently pursuing completion of such cure); or 

  
 33 

 CONFIDENTIAL 
  

 19.2.1.2 effective immediately upon written notice given by the non-bankrupt
Party, if the other Party files a petition in bankruptcy, or is adjudicated a bankrupt, becomes insolvent, makes an assignment for the benefit of creditors, is voluntarily or involuntarily dissolved, or has a receiver, trustee or other court officer
appointed for its property. 
 19.2.2 Termination by Cadence. In the event that Baxter does not agree to the assignment
by Cadence of this Agreement or any of Cadence’s rights or obligations hereunder to a competitor (as such term is defined in Section 23.1.3, below) of Baxter, Cadence may terminate this Agreement, effective thirty (30) days after
giving written notice to Baxter. 
  

	20.0	EFFECTS OF TERMINATION 

20.1 Payments. Termination will not relieve or release either Party from making any payments which may be due and owing under the
terms of this Agreement. 
 20.2 Non-cancelable Costs and Expenses. Upon termination of this Agreement, except by Cadence
as a result of a breach by Baxter under Section 19.2.1.1 or 19.2.1.2, Cadence shall reimburse Baxter for all Materials ordered prior to termination and not cancelable at no cost to Baxter. 

20.3 Disposal of API or Product. Upon termination of this Agreement, Baxter will promptly return all then remaining API to
Cadence, or if requested by Cadence and at Baxter’s option, destroy such API or deliver it for destruction to a third party qualified in such waste disposal. Return or destruction of API will be at the other Party’s expense if termination
is initiated by a Party pursuant to Sections 19.2.1.1 through 19.2.1.2 due to an act or omission of such other Party. Product shall be returned to Cadence promptly at Cadence’s expense and Cadence shall take delivery of and pay for all
undelivered Products that are manufactured and/or packaged pursuant to a Firm Order, at the price in effect at the time the Firm Order was placed; provided, that no such payment shall be due from Cadence if this Agreement is terminated by
Cadence pursuant to Section 19.2.1.1 or 19.2.1.2, including, but not limited to, termination for Baxter’s failure to provide sufficient quantities Products in accordance with the Product Specifications and cGMPs; or failure to provide such
Products in a timely manner. If Cadence is responsible for the expense of disposition of API, Product, or work-in-process, Cadence will pay Baxter all reasonable amounts due Baxter under this Section within thirty (30) days of receipt of
Baxter’s detailed invoice following completion of the designated return or destruction. 
 20.4 De-Installation Costs of
Cadence Owned Equipment. Cadence shall be entitled to physical possession of the Cadence Owned Equipment. Cadence agrees to reimburse Baxter for all reasonable costs incurred in the de-installation of Cadence Owned Equipment which includes
without limitation the removal, crating and transportation or shipping of Cadence Owned Equipment from the Facility to a location specified by Cadence. 

  
 34 

 CONFIDENTIAL 
  

 20.5 Restoration Costs of the Facility. Cadence agrees to reimburse Baxter for
all reasonable costs incurred in the restoration of the Facility to its pre-installation condition, as set forth in Section 20.6, including the repair of any damage to the Facility caused by or resulting from the removal of the Cadence Owned
Equipment, despite the exercise of reasonable care; provided, however, that Cadence shall not be liable for any such restoration costs with respect to any changes made to the Facility that Baxter reasonably agrees are usable by Baxter at the
time of removal of the Cadence Owned Equipment. 
 20.6 De-installation, Removal and Restoration Activities. The
de-installation, removal and restoration activities shall be conducted in a manner that is not unreasonably disruptive to, and does not impose unreasonable burdens on Baxter or its operations at the Facility. Baxter shall provide Cadence with a
written estimate of the cost of (i) such disassembly, crating and removal (ii) the disconnection of any and all connections to the Cadence Owned Equipment including without limitation electrical, air piping, conduits, dust collecting
ducts, in a manner which preserves in all material aspects the integrity of the structures and fixtures of the Facility, and (iii) the repair of any damage to the Facility, which despite the exercise of reasonable care, was caused by or
resulted from the removal of the machinery, equipment and any other fixed assets. Cadence shall be responsible for arranging for all transportation and shipping of the Cadence Owned Equipment being transferred from Facility to Cadence’s
location, including the timely application in its own name of any required licenses, permits or any other governmental authorization required to transfer the Cadence Owned Equipment. 

20.7 Technology Transfer. Upon the request of Cadence at any time during the Term of the Agreement, Baxter shall cooperate in the
technology transfer of the manufacture of the Products to a third-party supplier/manufacturer selected by Cadence in its sole discretion. In furtherance of the technology transfer, Baxter shall make its employees and other internal resources
reasonably available to Cadence and the designated third-party supplier/manufacturer and provide copies of all technology, documents, data and other information solely related to the Cadence Product License and the Baxter License. Any such
third-party supplier/ manufacturer that Cadence may designate to manufacture the Products shall be required to sign a customary and appropriate confidentiality agreement with Baxter with respect to the nondisclosure and the appropriate and limited
use of any Baxter Confidential Information transferred hereunder. With respect to all documents, data and other information provided in connection with this Section 20.7, (i) Baxter shall be responsible for the cost of providing a single
copy only; and (ii) in addition to paper and other tangible copies, Baxter shall, upon Cadence’s request, also provide to Cadence and/or the third-party supplier/manufacturer electronic copies of such documents, data and other information,
provided, that Baxter or its Affiliates have electronic copies thereof, and provided, further, that Baxter shall have no obligation to reformat or otherwise alter or modify any such electronic materials. Notwithstanding the
foregoing, this Section 20.7 shall not be 

  
 35 

 CONFIDENTIAL 
  

 
construed to give any other manufacturer, whether or not a competitor of Baxter, access to the Facility, information in Baxter’s Drug Master File [***], or right of reference to the Drug
Master File. Cadence shall reimburse Baxter for its reasonable costs associated with the transfer of technology contemplated by this Section 20.7. At the time of the requested technology transfer, Cadence and Baxter shall discuss the
feasibility and costs associated with Baxter providing to Cadence, in connection with such technology transfer, access to Baxter employees or consultants to facilitate the technology transfer. 

20.8 Baxter Non-Compete Obligation. Baxter hereby agrees that neither it nor any of its Affiliates shall develop or commercially
produce for itself or for any Third Party any intravenous formulation of product containing the Compound for distribution or sale in the Territory during the Initial Term and any renewals or extensions of this Agreement. 

20.9 Survival. Expiration or termination of the Agreement will not relieve the Parties of any obligation accruing prior to such
expiration or termination, and the provisions of Sections 12.2 (Warranties of Cadence), 12.3 (Warranties of Baxter), 5.1 (Product Registration Application Ownership), and Articles 13.0 (Confidentiality), 14.0 (Intellectual Property), 15.0
(Indemnification), 20.0 (Effects of Termination), 21.0 (Notices), 22.0 (Export), and 23.0 (Miscellaneous) will survive the expiration or termination of the Agreement. Any expiration or termination of this Agreement will be without prejudice to the
rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination. 
  

	21.0	NOTICES 

 All notices or
other communications which are required or permitted under this Agreement will be in writing and deemed delivered at the time they are personally delivered, or on the business day next following the date of confirmed transmission when sent by
facsimile, or two (2) business days after being sent by a nationally recognized overnight courier, and addressed as follows: 
 If to
Baxter: 
 Baxter Healthcare Corporation 
 BioPharma Solutions 
 25212 West Illinois Route 120 

Round Lake, Illinois 60073 
 Attention: General Manager 
 Fax No.: 847-270-3410 

With a copy to: 

Baxter Healthcare Corporation 
 One Baxter Parkway 
 Deerfield, Illinois 60015 

Attention: General Counsel 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 36 

 CONFIDENTIAL 
  

 Fax No.: 847-948-2450 

If to Cadence: 

Cadence Pharmaceuticals, Inc. 
 12481 High Bluff Drive, Suite 200 
 San Diego, CA 92130 

Attention: Chief Commercial Officer 
 Fax No: 858-436-1401 
 With a copy to: 

Cadence Pharmaceuticals, Inc. 
 12481 High Bluff Drive, Suite 200 
 San Diego, CA 92130 

Attention: General Counsel 
 Fax No: 858-436-8510 
  

	22.0	EXPORT 

 Each Party will
adhere to the United States Export Administration Laws and Regulations and will not export or re-export any technical data or Information received from the disclosing Party or the direct product of such technical data or Information to any
proscribed country listed in the United States Export Administration Regulations, unless properly authorized by the United States Government. 
  

	23.0	MISCELLANEOUS 

  

	 	23.1	Binding Effect; Assignment. 

 23.1.1 This Agreement will be binding upon and inure to the benefit of the Parties and their successors and permitted assigns. 

23.1.2 Baxter may not assign this Agreement or any of its rights or obligations hereunder except with the written consent of
Cadence, such consent not to be unreasonably withheld; provided, however, that Baxter may arrange for subcontractors to perform specific testing services arising under this Agreement without the consent of Cadence; provided,
further, that Baxter shall provide advance notice of the name and function of any such subcontractor and shall ensure such subcontractor’s adherence to the terms of this Agreement, including, but not limited to, the obligations of
confidentiality set forth in Section 13.0. 
 23.1.3 Cadence may assign this Agreement or any of its rights or
obligations hereunder, except to a competitor of Baxter, without approval from Baxter; provided, however, that Cadence shall give prior written notice of any assignment to Baxter, any assignee shall covenant in writing with Baxter to
be bound by the terms of this Agreement and Cadence shall remain liable hereunder. For the purposes of this Section 23.1.3, “competitor” means [***]. 

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 37 

 CONFIDENTIAL 
  

 23.1.4 Notwithstanding the foregoing provisions of this Section 23.1, either
Party may assign this Agreement to any of its Affiliates or to a successor to, purchaser or licensee of all or substantially all of its business, provided, that such assignee agrees in writing to be bound hereunder. For purposes of the
foregoing, the phrase “all or substantially all of its business” shall mean, with respect to Cadence, the business of Cadence relating to the Product and not necessarily any other products to which Cadence may have rights. 

23.2 Entire Agreement. This Agreement, together with its Exhibits (including without limitation the Confidential Disclosure
Agreement) contains the entire agreement between the Parties relating to the subject matter hereof and all prior written and verbal proposals, discussions, writings, and other understandings, by and between the Parties and relating to the subject
matter, are superseded hereby, including the LOI. None of the terms of this Agreement will be deemed to be waived by either Party or amended, unless such waiver or amendment is in writing executed by both Parties and such writing recites
specifically that it is a waiver of or an amendment to the terms of this Agreement. 
 23.3 Governing Law. This Agreement
will be deemed to have been entered into in the State of New York and its interpretation and construction and the remedies for its enforcement or breach are to be applied pursuant to and in accordance with the laws of the State of New York without
regard to the United Nations Convention on Contracts for the International Sale of Goods and without giving effect to any choice of laws rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State
of New York, to the rights and duties of the Parties. 
 23.4 Severability. In the event that any one or more of the
provisions contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby,
unless the absence of the invalidated provision(s) adversely affect the substantive rights of the Parties. The Parties agree to replace any invalid provision or parts thereof by new provision(s) which closely approximate the economic and proprietary
results intended by the Parties. 
 23.5 Waiver. The waiver by either Party hereto of any right hereunder or of a
material breach by the other Party will not be deemed a waiver of any other right hereunder or of any other material breach by said other Party whether of a similar nature or otherwise. 

23.6 Review with Counsel. Each Party agrees that it has had the opportunity to review this Agreement with its legal counsel.
Accordingly, the rule of construction that any ambiguity in this Agreement is to be construed against the drafting Party will not apply. 
  

  
 38 

 CONFIDENTIAL 
  

 23.7 Counterparts. This Agreement may be executed in two counterparts, by
original or facsimile signature, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [Remainder of page intentionally left blank.] 

  
 39 

 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the Parties have
executed this Agreement by their duly authorized representatives as of the date first set forth above. 
  

									
	CADENCE PHARMACEUTICALS, INC.	 	 	 	BAXTER HEALTHCARE CORPORATION
					
	By:	 	 /s/ Theodore R. Schroeder
	 		 	By:	 	 /s/ Brik V. Eyre

	Name:	 	Theodore R. Schroeder	 		 	Name:	 	Brik V. Eyre
	Title:	 	President and Chief Executive Officer	 		 	Title:	 	General Manager
	Date:	 	January 28, 2011	 		 	Date:	 	January 28, 2011

  
 40 

 EXHIBIT A 
 PRODUCT SPECIFICATIONS 
 I. DESCRIPTION 

The drug product is a [***] formulation of acetaminophen intended for intravenous infusion with the composition described in Table 1.

 Table 1: Each 100mL contains Composition of Acetaminophen, Injection for Intravenous Use. 

 

					
	 Component
	  	 Unit Formula
	  	 Quality Standard

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 II. MANUFACTURING
METHOD (the “Formulation Specifications”) 
 The Product will be manufactured according to and will meet the specification of the
approved NDA 22-450. 
 The method of formulation is also described in Baxter Document [***] and other documents referenced therein. 

The Product will be sterilized consistently to the agreement Baxter has with the FDA regarding [***] as described in Baxter DMF [***]. 

The Product shelf life specifications are provided in Table 2. For certain parameters at time of release the drug product will meet tighter limits
provided in Table 3. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  
  

 Table 2: Regulatory (Shelf Life) Specification for the Product 

 

							
	 Attribute
	  	 Test
	  	 Reference
	  	 Acceptance Criteria

	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	
	 Table 3: In-house Limits at Time of Release for the Product

 

	 Attribute
	  	 Test
	  	 Reference
	  	 Acceptance Criteria

	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

  

 III. CONTAINER CLOSURE SYSTEM (the “Container”) 

Acetaminophen, injection for intravenous use 1,000 mg/100 mL (10 mg/mL) is packaged in [***]. The details of the container closure system are provided in
Table 4. The vials will be labeled with a hanger style label. The content of the label will be as approved in NDA 22-450. 
 Table 4:
Container Closure System 
  

					
	 Component
	  	 Material
	  	 Supplier

	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]

 IV. PACKAGING 

Twenty-four vials will be packaged in a carton. The carton will be labeled according to the approved NDA 22-450 and contain one package insert with
wording approved in NDA 22-450. 
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT B 
 API SPECIFICATIONS 
 NDA 22-450 Specification Limits for Acetaminophen

  

					
	 TEST
	  	 TEST METHOD
	  	 LIMITS

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT C 
 MINIMUM BATCH SIZE AND MANUFACTURING FEE 
  

	A.	Minimum Batch Size: As of the Effective Date, the “Minimum Batch Size” for the Product is [***] vials. 

 

	B.	Manufacturing Fee: The “Manufacturing Fee” for the Product shall be as set forth below: 

 

									
	 [***]

	 	  	 [***]

	 	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  		  		  		  	
	[***]	  		  		  		  	

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT D 
 COST OF API AND 
 METHODOLOGY FOR CALCULATING MANUFACTURING YIELD LOSSES

  

			
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT E 
 BAXTER OWNED EQUIPMENT 
 [***] 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT F 
 CADENCE OWNED EQUIPMENT 
 The following list details the Cadence Owned Equipment as of the
Effective Date. Cadence may amend this list from time to time by providing written notice to Baxter as follows: 
 Baxter
Healthcare Corporation 
 BioPharma Solutions 
 25212 West Illinois Route 120 
 Round Lake, Illinois 60073 

Attention: General Manager 
 Fax No.:    847-270-3410 
  

					
	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
			
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

					
	 [***]
	  	[***]	  	[***]
			
		  	[***]	  	[***]
			
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
	     [***] [***]
	  	[***]

  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT G 
 CONFIDENTIAL DISCLOSURE AGREEMENT 
 [***] 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT H 
 DEVELOPMENT PLAN TEMPLATE 
  

 
  

DEVELOPMENT PLAN #[    ] 
 DESCRIPTION: [Insert purpose of Development Plan] 
 DATE:

 Once executed, this Development Plan # [    ], shall be incorporated by reference as part of the
Amended & Restated Development & Supply Agreement between Cadence Pharmaceuticals, Inc. and Baxter Healthcare Corporation dated January [    ], 2011 (the “Agreement”). 

 

	
	APPROVALS

  

					
	CADENCE APPROVALS	 		 	BAXTER APPROVALS
			
	  
	 		 	
	(Signature/Date)	 		 	  

(Signature/Date)

	  
	 		 	  

	 (Printed Name/Title)

and
	 		 	 (Printed Name/Title)

and

	  
	 		 	  

	(Legal Signature/Date)	 		 	(Contract Management Signature/Date)
	  
	 		 	  

	(Printed Name/Title)	 		 	(Printed Name/Title)

  

	
	TABLE OF CONTENTS

 Purpose of the Development Plan 
 Scope of Activities 

Functional Assessments 
 Pricing 
 Other 

 

	
	I. PURPOSE OF THE DEVELOPMENT PLAN

 By this
Development Plan, Cadence and Baxter intend to conduct the following development project [outline high level description of the purpose]. 
  

	
	II. SCOPE OF ACTIVITIES

  

			
	 Scope of the Development Plan
	  	 By this Development Plan, Cadence and Baxter intend to [outline scope of the activities.]

[Formulation and analytical development, Specifications (API and Product Specifications), Facility improvements, Equipment/material purchases, clinical
production, stability studies, pre-commercial activities.]

	 Documentation/
 Materials to be Provided by

Baxter
	  	 Baxter will be responsible for or otherwise provide:

 

—

		
	 Documentation/

Materials to be Provided by

Cadence
	  	 Cadence will be responsible for or otherwise provide:

 

—

		
	 Baxter Development Deliverables
	  	
		
	 Cadence Development
	  	
		
	 Deliverables
	  	

	
	III. FUNCTIONAL ASSESSMENT and REVIEW

  

			
	Regulatory Strategy	  	        [The current Regulatory Plan is not impacted by this Development Plan.]
	Other	  	

  
  

	
	IV. PRICING

  

			
	Description	    	Price
	 Outline description of activities to be performed under this Development Plan
	    	

  

	
	IV. OTHER [Example: Cadence Owned Equipment, Baxter Owned Equipment.]

 EXHIBIT I 
 DEFINITIONS 
 (Section 2.0) 

As used in this Agreement the following terms will have the following meanings: 
 The term “ADR” will have the meaning set forth in Section 16.0. 
 The term
“Affiliate” will mean any corporation or business entity that controls, is controlled by, or is under common control with, Cadence or Baxter. A corporation or business entity will be deemed to control another corporation or business
entity if it owns, directly or indirectly, fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock, or general partnership interest of such corporation or business entity. 

The term “API” will mean the Compound supplied to Baxter by Cadence in accordance with the terms of this Agreement and the API
Specifications set forth in Exhibit B, as amended by Cadence from time to time. 
 The term “API/Formulation
Specifications” will have the meaning set forth in Section 14.2.1. 
 The term “Applicable Laws” will mean all
laws, ordinances, rules and regulations within the Territory applicable to the manufacture of the Product by Baxter, and the obligations of Baxter or Cadence thereunder, as the context requires, including, without limitation, (i) all applicable
federal, state and local laws and regulations of each jurisdiction within the Territory; (ii) the FD&C Act; (iii) the cGMPs; and (iv) all applicable environmental and health and safety laws. 

The term “Background Intellectual Property Rights” will mean all Patents, Patent Applications, copyrights, trade secrets, and other
intellectual property rights owned by either Party or under which a Party otherwise has the right to grant licenses without accounting to any third party or to the other Party, where the inventions claimed, the works of authorship, or the know-how,
trade secrets and the like, were not made in performance of activities pursuant to, or in anticipation of, this Agreement. For the avoidance of doubt, Baxter Background Intellectual Property rights do not include any such intellectual property
rights developed by Baxter in its Grosotto facility and which is owned or licensed to the licensor of Cadence Licensed Intellectual Property. 

The term “Batch Disposition Certificate” will mean the document signed by Baxter and provided to Cadence that sets forth Baxter’s
recommendation to release a batch. 
 The term “Baxter Development Deliverables” will have the meaning set forth in
Section 4.2.1. 
 The term “Baxter Inventions” will have the meaning set forth in Section 14.1.3. 

The term “Baxter Owned Equipment” will have the meaning set forth in Section 9.2. 

The term “Baxter License” will have the meaning set forth in Section 14.3.2. 

 The term “Cadence Development Deliverables” will have the meaning set forth in
Section 4.2.1. 
 The term “Cadence Owned Equipment” will have the meaning set forth in Section 9.3. 

The term “Cadence Inventions” will have the meaning set forth in Section 14.1.2. 

The term “Cadence Licensed Intellectual Property” will mean those certain Patents and Patent Applications licensed and/or sublicensed to
Cadence pursuant to the IV APAP Agreement and the Pharmatop License Agreement. 
 The term “Capacity Increase Development Plan”
will have the meaning set forth in Section 4.1.2. 
 The term “Cadence Product License” will have the meaning set forth in
Section 14.3.1. 
 The term “Commercially Reasonable Efforts” will mean the application by a Party, consistent with the
exercise of prudent technical and business judgment, of diligent and sustained efforts and of material resources to fulfill the obligation in issue, consistent with the efforts a Party would devote to a pharmaceutical product of similar market and
profit potential or strategic value at a similar stage in development or product life as the Product in issue, based on conditions then prevailing. 
 The term “competitor” will have the meaning set forth in Section 23.1.3. 

The term “Communications” will have the meaning set forth in Section 5.3. 
 The term “Compound” will mean N-acetyl-para-aminophenol (CAS Registry No. 103-90-2), also commonly referred to as acetaminophen and/or paracetamol. 

The term “Confidential Disclosure Agreement” will mean the two-way disclosure agreement, effective April 6, 2006, a copy of which
is attached to this Agreement as Exhibit G. 
 The term “Confidential Information” will have the meaning set forth in
the Confidential Disclosure Agreement. 
 The term “Container” will mean the container portion of the Product, as described in
Exhibit A, Section III, as may be amended from time to time in accordance with the Quality Agreement. 
 The term
“Contract Year” will mean the twelve (12) consecutive month period beginning on November 1, 2010, and each subsequent twelve (12) consecutive month period thereafter. 

The term “cGMP” or “Current Good Manufacturing Practices” will mean the good manufacturing practices required by the
FDA and set forth in the FD&C Act or FDA regulations, policies, or guidelines (including ICH adopted guidelines) in effect at a particular time, for the manufacture and testing of pharmaceutical materials. 

The term “Damages” will have the meaning set forth in Section 15.1. 

 The term “Deficiency Notice” will have the meaning set forth in Section 10.2.

 The term “Development Plan” will have the meaning set forth in Section 4.1.3. 

The term “DMF [***]” means Baxter’s Type III Drug Master File Number [***]. 

The term “Drug Product Manufacturing Process” will have the meaning set forth in Section 10.8. 

The term “Effective Date” will have the meaning set forth in the preamble to this Agreement. 

The term “Estimated Requirements” will have the meaning set forth in Section 6.3. 

The term “Equipment Failure Event” will have the meaning set forth in Section 9.5. 

The term “Facility” will mean Baxter’s manufacturing facility in Cleveland, Mississippi. 

The term “FDA” will mean the United States Food and Drug Administration and any successor agency and the corresponding regulatory
authority of each jurisdiction in the Territory. 
 The term “FD&C Act” will mean the United States Federal Food, Drug and
Cosmetic Act, as amended, or any corresponding Act of each jurisdiction in the Territory. 
 The term “Field” will mean the
development, registration and manufacture of, the Product. 
 The term “Force Majeure” will have the meaning set forth in
Section 17.1. 
 The term “Formulation” will mean any and all premix, ready-to-use formulations containing the Compound.

 The term “Formulation Specifications” will mean the Manufacturing Method for the Product, as described in Exhibit A,
Section II, as may be amended from time to time in accordance with the Quality Agreement. 
 The term “Improvements” shall
have the meaning set forth in Section 7.4. 
 The term “Information” will mean (i) techniques and data relating to
the Field, including, but not limited to, ideas (including patentable inventions), inventions, practices, methods, knowledge, trade secrets, documents, apparatus, clinical and regulatory strategies, test data (including pharmacological,
toxicological and clinical test data), analytical and quality control data, manufacturing, Patent and legal data, market data, financial data within the Field and (ii) chemical formulations, compositions of matter, product samples and assays
within the Field. 
 The term “Initial Term” will have the meaning set forth in Section 19.1. 

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 The term “IV APAP Agreement” shall mean that certain IV APAP Agreement (US and Canada)
dated February 21, 2006, by and between Bristol-Myers Squibb Company and Cadence, as the same may be amended from time to time. 
 The term
“Joint Inventions” will have the meaning set forth in Section 14.1.4. 
 The term “Joint Patent
Applications” will have the meaning set forth in Section 14.4.2. 
 The term “Line 1” will mean the Product
manufacturing line in operation as of the Effective Date. 
 The term “Line 2” will mean a second Product manufacturing line
planned for installation at the Facility. 
 The term “LOI” will have the meaning set forth in Section 1.0. 

The term “Manufacturing Fee” will mean the fee per unit paid by Cadence to Baxter for Product manufactured under this Agreement as
described in Section 7.1 and Exhibit C. 
 The term “Materials” shall mean (i) all raw materials, components,
work-in-process and other ingredients required to manufacture the Product except for the API, and (ii) all packaging materials used in the manufacture, storage and shipment of Product. 
 The term “Matter” will have the meaning set forth in Section 15.3. 
 The
term “Minimum Batch Size” will have the meaning set forth in Exhibit C. 
 The term “Minimum Purchase
Requirements” will have the meaning set forth in Section 6.2.2. 
 The term “NDA” will mean a New Drug
Application, as defined in the FD&C Act and applicable regulations promulgated thereunder, as amended from time to time, or any corresponding foreign application, registration, or certification of each jurisdiction in the Territory. 

The term “Normal Manufacturing Process” shall mean the process beginning upon the mixing of the API by Baxter and ending when the
finished Product is released into finished goods inventory at the Facility. 
 The term “Original Agreement” will have the
meaning set forth in Section 1.0. 
 The term “Original Effective Date” shall mean July 18, 2007. 

The term “Original Product Data” will have the meaning set forth in Section 14.2.1. 

The term “Party” or “Parties” will mean Cadence and Baxter individually, and collectively, as applicable. 

 The term “Patent” will mean (i) valid and enforceable letters patent including any
extension, registration, continuation, reissue, reexamination or renewal thereof and (ii) to the extent valid and enforceable rights are granted by a governmental authority thereunder, a Patent Application. 

The term “Patent Application” will mean an application for letters patent. 
 The term “Pharmatop License Agreement” shall mean that certain License Agreement dated December 23, 2002, between SCR Pharmatop and Bristol-Myers Squibb Company, as the same may be
amended from time to time. 
 The term “Preexisting Specifications” will have the meaning set forth in Section 14.2.1.

 The term “Product” will mean a premix, ready-to-use solution incorporating API that has (i) undergone the formulation
process established under the Development Program and (ii) been packaged and terminally sterilized within the Container, all in accordance with the Product Specifications. 
 The term “Product Manager” will have the meaning set forth in Section 3. 

The term “Product Specifications” will mean the Product Specifications set forth in Exhibit A, as amended from time to time in
accordance with the Quality Agreement. 
 The term “Quality Agreement” will mean the Quality Agreement executed by the Parties
effective December 18, 2007, as amended from time to time by the mutual agreement of the Parties. 
 The term “Regulating
Groups” will mean the FDA and its successors, and similar governmental agencies outside the United States and in the Territory, which are responsible for granting manufacturing, marketing, price and/or reimbursement price authorizations and
includes applicable national, supra-national (e.g. the European Commission or the Council of the European Union), state or local Regulating Groups, department, bureau, commission, council or other governmental entity in the Territory that has
jurisdiction over the API, Compound, Formulation or Product, whether the development, manufacture, handling, storage, transportation, destruction, or otherwise. 
 The term “Regulatory Submissions” will mean those applications and filings for the Product required by FDA regulations, as amended from time-to-time, and the equivalent applications and
filing for each country or super-national jurisdiction in the Territory, including but not limited to, any NDA or Investigational New Drug Application (INDA). 
 The term “Reports” will have the meaning set forth in Section 14.2.1. 
 The
term “Requirements” will mean Cadence’s actual requirements for the Product for use or sale in the Territory. 
 The term
“Routine Maintenance” will mean the maintenance to be performed by Baxter based on a preventative maintenance schedule to be agreed upon within thirty (30) days following the Effective Date by Cadence and Baxter, as amended
from time to time upon the mutual agreement of the Parties.  

 The term “Senior Executives” will have the meaning set forth in Section 3.2.

 The term “Specified Equipment” will mean the Cadence Owned Equipment identified with an asterisk in Exhibit F.

 The term “Steering Committee” will have the meaning set forth in Section 3.2. 

The term “Term of the Agreement” will have the meaning set forth in Section 19.1. 

The term “Territory” will mean the United States. 
 The term “Third Party” will mean any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship, or other business organization who is not a
Party or an Affiliate of a Party to this Agreement.Registration Rights Agreement

 Exhibit 4.1 
 CROWN AMERICAS LLC 
 and 

CROWN AMERICAS CAPITAL CORP. III 
 $700,000,000 6 1/4% Senior Notes due 2021 
 REGISTRATION RIGHTS AGREEMENT 

New York, New York 

January 31, 2011 
 Deutsche
Bank Securities Inc. 
     As Representative of the several Initial 
     Purchasers named in Schedule I hereto 
 c/o Deutsche Bank Securities Inc.

 60 Wall Street 
 New York, New York
10005 
 Dear Sirs: 
 Crown Holdings, Inc., a Pennsylvania corporation (“Crown”), and the indirect parent company of Crown Americas LLC, a Pennsylvania limited liability company (the
“Company”), and Crown Americas Capital Corp. III, a Delaware Corporation (“Crown Americas Capital III” and, together with the Company, the “Notes Issuers”), proposes among other things, that the
Notes Issuers issue and sell to the several initial purchasers named in Schedule I hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $700,000,000 aggregate
principal amount of their 6 1/4% Senior Notes due
2021 (the “Notes”) upon the terms and conditions set forth in a purchase agreement dated January 18, 2011 (the “Purchase Agreement”) relating to the initial placement of the Notes (the “Initial
Placement”). The Notes Issuers’ obligations under the Notes will be unconditionally guaranteed (the “Guarantees”) by Crown and each of Crown’s subsidiaries named in Schedule II to the Purchase Agreement
(collectively, the “Guarantors”). References herein to the “Issuers” refer to the Notes Issuers and the Guarantors. References herein to the “Securities” refer to the Notes and the Guarantees. To
induce the Initial Purchasers to enter into the Purchase Agreement and to satisfy a condition of your obligations thereunder, the Issuers hereby agree with you for your benefit and the benefit of the holders from time to time of Securities and
Exchange Securities (as defined below) (including the Initial Purchasers) (each a “Holder” and collectively the “Holders”) as follows: 
 1. Definitions. Capitalized terms used herein without definition shall have their respective meanings set forth in the Purchase Agreement. As used in this Agreement, the following defined terms
shall have the following respective meanings: 
 “Act” shall mean the Securities Act of 1933, as amended, and
the rules and regulations of the Commission promulgated thereunder. 

 “Affiliate” of any specified Person shall mean any other Person that,
directly or indirectly, is in control of, is controlled by, or is under common control with, such specified Person. For purposes of this definition, “control” of a Person shall mean the power, direct or indirect, to direct or cause
the direction of the management and policies of such Person whether by contract or otherwise; and the terms “controlling” and “controlled” shall have meanings correlative to the foregoing. 

“Broker-Dealer” shall mean any broker or dealer registered as such under the Exchange Act. 

“Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on which banking
institutions or trust companies are authorized or obligated by law to close in New York City. 
 “Crown Americas Capital
III” shall mean Crown Americas Capital Corp. III, a Delaware corporation, and any successor thereto. 

“Commission” shall mean the Securities and Exchange Commission. 

“Company” shall mean Crown Americas LLC, a Pennsylvania limited liability company, and any successor thereto.

 “Conduct Rules” shall have the meaning set forth in Section 4(u) hereof. 

“Crown” shall mean Crown Holdings, Inc., a Pennsylvania corporation, and any successor thereto. 

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the
Commission promulgated thereunder. 
 “Exchange Offer Registration Period” shall mean the one-year period
following the consummation of the Registered Exchange Offer, exclusive of any period during which any stop order shall be in effect suspending the effectiveness of the Exchange Offer Registration Statement. 

“Exchange Offer Registration Statement” shall mean a registration statement of the Issuers on an appropriate form under
the Act with respect to the Registered Exchange Offer, all amendments and supplements to such registration statement, including post-effective amendments thereto, in each case including the Prospectus contained therein, all exhibits thereto and all
material incorporated by reference therein. 
 “Exchange Securities” shall mean debt securities of the Notes
Issuers guaranteed by the Guarantors identical in all material respects to the Securities (except that the U.S. transfer restrictions shall be modified or eliminated as appropriate) to be issued under the Indenture. 

“Exchanging Dealer” shall mean any Holder (which may include any Initial Purchaser) that is a Broker-Dealer and elects
to exchange any Securities that it acquired for its own account as a result of market-making activities or other trading activities (but not directly from any Issuer or any Affiliate of any Issuer) for Exchange Securities. 

“Final Memorandum” shall have the meaning set forth in the Purchase Agreement. 

“Guarantees” shall have the meaning set forth in the preamble hereto. 

“Guarantors” shall have the meaning set forth in the preamble hereto. 

  
 -2-

 “Holder” shall have the meaning set forth in the preamble hereto.

 “Indenture” shall mean the Indenture relating to the Securities to be dated as of the date of original
issuance of the Notes among the Notes Issuers, the Guarantors and The Bank of New York Mellon Trust Company, N.A., as trustee, as amended or supplemented from time to time in accordance with the terms thereof. 

“Initial Placement” shall have the meaning set forth in the preamble hereto. 

“Initial Purchasers” shall have the meaning set forth in the preamble hereto. 

“Issue Date” shall mean January 31, 2011, the date of first issuance of the Securities. 

“Issuers” shall have the meaning set forth in the preamble hereto. 

“Losses” shall have the meaning set forth in Section 6(d) hereof. 

“Majority Holders” shall mean, on any date, Holders of a majority of the aggregate principal amount of Securities and
Exchange Securities registered under a Registration Statement. 
 “Managing Underwriters” shall mean the
investment banker or investment bankers and manager or managers that shall administer an underwritten offering. 

“Notes” shall have the meaning set forth in the preamble hereto. 

“Person” shall mean an individual, trustee, corporation, partnership, limited liability company, joint stock company,
trust, unincorporated association, union, business association, firm or other legal entity. 
 “Prospectus”
shall mean the prospectus included in any Registration Statement (including, without limitation, a prospectus that discloses information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule
430A under the Act and any “issuer free writing prospectus” as defined in Rule 433 under the Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Securities or the
Exchange Securities covered by such Registration Statement, and all amendments and supplements thereto, including any and all exhibits thereto and any information incorporated by reference therein. 

“Purchase Agreement” shall have the meaning set forth in the preamble hereto. 

“Registered Exchange Offer” shall mean the proposed offer of the Issuers to issue and deliver to the Holders of the
Securities that are not prohibited by any law or policy of the Commission from participating in such offer, in exchange for the Securities, a like aggregate principal amount of the Exchange Securities. 

“Registration Default” shall have the meaning set forth in Section 8 hereof. 

“Registration Statement” shall mean any Exchange Offer Registration Statement or Shelf Registration Statement that
covers any of the Securities or the Exchange Securities pursuant to the provisions of this Agreement, any amendments and supplements to such registration statement, including post-effective amendments (in each case including the Prospectus contained
therein), all exhibits thereto and all material incorporated by reference therein. 
 “Representatives” shall
have the meaning set forth in the preamble hereto. 

  
 -3-

 “Securities” shall have the meaning set forth in the preamble hereto.

 “Shelf Registration” shall mean a registration effected pursuant to Section 3 hereof. 

“Shelf Registration Period” shall have the meaning set forth in Section 3(b) hereof. 

“Shelf Registration Statement” shall mean a “shelf” registration statement of the Issuers pursuant to the
provisions of Section 3 hereof which covers some or all of the Securities or Exchange Securities, as applicable, on an appropriate form under Rule 415 under the Act, or any similar rule that may be adopted by the Commission, amendments and
supplements to such registration statement, including post-effective amendments, in each case including the Prospectus contained therein, all exhibits thereto and all material incorporated by reference therein. 

“Trustee” shall mean the trustee with respect to the Securities under the Indenture. 

“Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended, and the rules and regulations of the
Commission promulgated thereunder. 
 “underwriter” shall mean any underwriter of Securities or Exchange
Securities in connection with an offering thereof under a Shelf Registration Statement. 
 2. Registered Exchange Offer.

 (a) The Issuers shall prepare and use their reasonable best efforts to file with the Commission and cause to become effective
the Exchange Offer Registration Statement with respect to the Registered Exchange Offer. The Issuers shall use their reasonable best efforts to cause the Registered Exchange Offer to become completed under the Act within 360 days of the Issue Date
(or if such 360th day is not a Business Day, the next succeeding Business Day). 
 (b) Upon the effectiveness of the Exchange
Offer Registration Statement, the Issuers shall promptly commence the Registered Exchange Offer, it being the objective of such Registered Exchange Offer to enable each Holder electing to exchange Securities for Exchange Securities (provided that
such Holder (i) is not an Affiliate of any Issuer, (ii) acquires the Exchange Securities in the ordinary course of such Holder’s business, (iii) has no arrangements with any Person to participate in the distribution of the
Exchange Securities, (iv) is not prohibited by any law or policy of the Commission from participating in the Registered Exchange Offer and (v) is not an Initial Purchaser holding Securities that have the status of an unsold allotment
remaining from the initial distribution of the Securities) to trade such Exchange Securities from and after their receipt without any limitations or restrictions under the Act and without material restrictions under the securities laws of a
substantial proportion of the several states of the United States. 
 (c) In connection with the Registered Exchange Offer, the
Issuers shall: 
 (i) cause to be delivered to each Holder a copy of the Prospectus forming part of the Exchange
Offer Registration Statement, together with an appropriate letter of transmittal and related documents; 
 (ii)
keep the Registered Exchange Offer open for not less than 20 Business Days after the date notice thereof is mailed to the Holders (or longer if required by applicable law) and consummated such Registered Exchange Offer no later than the 35th day
after the date notice thereof is mailed to the Holders (or longer if required by applicable law); 

  
 -4-

 (iii) use their reasonable best efforts to keep the Exchange Offer
Registration Statement continuously effective under the Act, supplemented and amended as required under the Act, to ensure that it is available for sales of Exchange Securities by Exchanging Dealers during the Exchange Offer Registration Period;

 (iv) utilize the services of a depositary for the Registered Exchange Offer with an address in the Borough of
Manhattan in New York City, which may be the Trustee or an Affiliate of the Trustee; 
 (v) permit Holders to
withdraw tendered Securities at any time prior to the close of business, New York time, on the last Business Day on which the Registered Exchange Offer is open; 
 (vi) if requested by the Commission, prior to effectiveness of the Exchange Offer Registration Statement, provide a supplemental letter to the Commission (A) stating that the Issuers are conducting
the Registered Exchange Offer in reliance on the position of the Commission in Exxon Capital Holdings Corporation (pub. avail. May 13, 1988) and Morgan Stanley and Co., Inc. (pub. avail. June 5, 1991); and (B) including
a representation that the Issuers have not entered into any arrangement or understanding with any Person to distribute the Exchange Securities to be received in the Registered Exchange Offer and that, to the best of the Issuers’ information and
belief, each Holder participating in the Registered Exchange Offer is acquiring the Exchange Securities in the ordinary course of business and has no arrangement or understanding with any Person to participate in the distribution of the Exchange
Securities; and 
 (vii) comply in all respects with all laws applicable to the Registered Exchange Offer.

 (d) As soon as practicable after the close of the Registered Exchange Offer, the Issuers shall: 

(i) accept for exchange all Securities validly tendered and not validly withdrawn pursuant to the Registered Exchange
Offer; 
 (ii) deliver to the Trustee for cancellation in accordance with Section 4(s) hereof all Securities
so accepted for exchange; and 
 (iii) cause the Trustee promptly to authenticate and deliver to each Holder of
Securities a principal amount of Exchange Securities equal to the principal amount of the Securities of such Holder so accepted for exchange. 
 (e) Each Holder hereby acknowledges and agrees that any Broker-Dealer and any such Holder using the Registered Exchange Offer to participate in a distribution of the Exchange Securities (x) could not
under Commission policy as in effect on the date of this Agreement rely on the position of the Commission in Morgan Stanley and Co., Inc. (pub. avail. June 5, 1991) and Exxon Capital Holdings Corporation (pub. avail. May 13,
1988), as interpreted in the Commission’s letter to Shearman & Sterling dated July 2, 1993 and similar no-action letters; and (y) must comply with the registration and prospectus delivery requirements of the Act in connection
with any secondary resale transaction which must be covered by an effective registration statement containing the selling security holder information required by Item 507 or 508, as applicable, of Regulation S-K under the Act if the resales are
of Exchange Securities obtained by such Holder in exchange for Securities acquired by such Holder directly from any Issuer or one of its Affiliates. Accordingly, each Holder participating in the Registered Exchange Offer shall be required to
represent to the Issuers that, at the time of the consummation of the Registered Exchange Offer: 

  
 -5-

 (i) any Exchange Securities received by such Holder will be acquired in the
ordinary course of business; 
 (ii) such Holder will have no arrangement or understanding with any Person to
participate in the distribution of the Securities or the Exchange Securities within the meaning of the Act; and 

(iii) such Holder is not an Affiliate of any Issuer. 

(f) If any Initial Purchaser determines that it is not eligible to participate in the Registered Exchange Offer with respect to the
exchange of Securities constituting any portion of an unsold allotment, at the request of such Initial Purchaser, the Issuers shall issue and deliver to such Initial Purchaser or the Person purchasing Exchange Securities registered under a Shelf
Registration Statement as contemplated by Section 3 hereof from such Initial Purchaser, in exchange for such Securities, a like principal amount of Exchange Securities. The Issuers shall use their reasonable best efforts to cause the same CUSIP
and ISIN numbers to be assigned for such Exchange Securities as for Exchange Securities issued pursuant to the Registered Exchange Offer. 
 (g) Interest on each Exchange Security shall accrue from (A) the later of (x) the last date on which interest was paid on the Security surrendered in exchange therefor or (y) if the
Security is surrendered for exchange on a date that is after the record date for an interest payment that will occur on or after the date of such exchange and as to which interest will be paid, the date of such interest payment date, or (B) if
no interest has been paid on such Security, from the date of such Security’s original issue. 
 3. Shelf
Registration. 
 (a) If (i) due to any change in law, Commission policy or applicable interpretations or either of the
foregoing by the Commission’s staff, the Issuers determine upon advice of their outside counsel that they are not permitted to effect the Registered Exchange Offer as contemplated by Section 2 hereof; (ii) for any other reason the
Registered Exchange Offer is not completed within 360 days after the Issue Date; (iii) prior to the 20th day following the consummation of the Registered Exchange Offer (x) any Initial Purchaser so requests with respect to Securities
that are not eligible to be exchanged for Exchange Securities in the Registered Exchange Offer and that are held by it following consummation of the Registered Exchange Offer, (y) any Holder notifies the Notes Issuers that it is not or was not
eligible to participate in the Registered Exchange Offer or (z) in the case of any Initial Purchaser that participates in the Registered Exchange Offer or acquires Exchange Securities pursuant to Section 2(f) hereof, such Initial Purchaser
notifies the Notes Issuers that it will not or did not receive freely tradeable Exchange Securities in exchange for Securities constituting any portion of an unsold allotment (it being understood that (A) the requirement that an Initial
Purchaser deliver a Prospectus containing the information required by Item 507 or 508 of Regulation S-K under the Act in connection with sales of Exchange Securities acquired in exchange for such Securities shall result in such Exchange
Securities being not “freely tradeable”; and (B) the requirement that an Exchanging Dealer deliver a Prospectus in connection with sales of Exchange Securities acquired in the Registered Exchange Offer in exchange for Securities
acquired as a result of market-making activities or other trading activities shall not result in such Exchange Securities being not “freely tradeable”), the Issuers shall, effect a Shelf Registration in accordance with Section 3(b)
hereof. 
 (b) If a Shelf Registration Statement is required to be filed and declared effective pursuant to this Section 3:

 (i) the Issuers shall as promptly as practicable (but in no event more than 60 days after so required or
requested pursuant to this Section 3), file with the Commission, and thereafter shall use their reasonable best efforts to cause to be declared effective under the Act within 60 days after the filing

  
 -6-

 
thereof with the Commission, a Shelf Registration Statement relating to the offer and sale of the Securities or the Exchange Securities, as applicable, by the Holders thereof from time to time in
accordance with the methods of distribution elected by such Holders and set forth in such Shelf Registration Statement; provided, however, that no Holder (other than an Initial Purchaser) shall be entitled to have the Securities or the
Exchange Securities, as applicable, held by it covered by such Shelf Registration Statement unless such Holder agrees in writing to be bound by all of the provisions of this Agreement applicable to such Holder; and provided, further,
that with respect to Exchange Securities received by an Initial Purchaser in exchange for Securities constituting any portion of an unsold allotment, the Issuers may, if permitted by current interpretations by the Commission’s staff, file a
post-effective amendment to the Exchange Offer Registration Statement containing the information required by Item 507 or 508 of Regulation S-K, as applicable, in satisfaction of their obligations under this subsection with respect thereto, and
any such Exchange Offer Registration Statement, as so amended, shall be referred to herein as, and governed by the provisions herein applicable to, a Shelf Registration Statement. 

(ii) The Issuers shall use their reasonable best efforts to keep the Shelf Registration Statement continuously effective,
supplemented and amended as required by the Act, in order to permit the Prospectus forming part thereof to be usable by Holders until the earliest of (x) one year from the effective date of the Shelf Registration Statement and (y) the date
on which all the Securities or Exchange Securities, as applicable, covered by the Shelf Registration Statement have been sold pursuant to the Shelf Registration Statement (in any such case, such period being called the “Shelf Registration
Period”). The Issuers shall be deemed not to have used their reasonable best efforts to keep the Shelf Registration Statement effective during the requisite period if any of them voluntarily takes any action that would reasonably be
expected to result in Holders of Securities or Exchange Securities covered thereby not being able to offer and sell such Securities or Exchange Securities during that period, unless (A) such action is required by applicable law; or
(B) such action is taken by such Issuer in good faith and for valid business reasons (not including avoidance of its obligations hereunder), including the acquisition or divestiture of assets, so long as the Issuers thereafter comply with the
requirements of Section 4(k) hereof, if applicable. 
 (iii) The Issuers shall cause the Shelf Registration
Statement and the related Prospectus and any amendment or supplement thereto, as of the effective date of the Shelf Registration Statement or such amendment or supplement, (A) to comply in all material respects with the applicable requirements
of the Act and the rules and regulations of the Commission; and (B) not to contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading. 
 4. Additional Registration Procedures. In
connection with any Shelf Registration Statement and, to the extent applicable, any Exchange Offer Registration Statement, the following provisions shall apply: 
 (a) The Issuers shall: 
 (i) furnish to each of you, not less than
five Business Days prior to the filing thereof with the Commission, a copy of any Exchange Offer Registration Statement and any Shelf Registration Statement, and each amendment thereof and each amendment or supplement, if any, to the Prospectus
included therein (including all documents incorporated by reference therein after the initial filing) and shall use their reasonable best efforts to reflect in each such document, when so filed with the Commission, such comments as you reasonably
propose; 

  
 -7-

 (ii) in the case of an Exchange Offer Registration Statement, to the extent
permitted by the Act, include the information set forth in Annex A hereto on the front cover of the Prospectus included in the Exchange Offer Registration Statement, in Annex B hereto in the forepart of the Exchange Offer
Registration Statement in a section setting forth details of the Registered Exchange Offer, in Annex C hereto in the underwriting or plan of distribution section of the Prospectus contained in the Exchange Offer Registration Statement,
and in Annex D hereto in the letter of transmittal delivered pursuant to the Registered Exchange Offer; 
 (iii) in the case of an Exchange Offer Registration Statement, if requested by an Initial Purchaser, include the information required by Item 507 or 508 of Regulation S-K, as applicable, in the
Prospectus contained in the Exchange Offer Registration Statement; and 
 (iv) in the case of a Shelf
Registration Statement, include the names of the Holders that propose to sell Securities or Exchange Securities pursuant to the Shelf Registration Statement as selling security holders. 

(b) The Issuers shall ensure that: 

(i) any Registration Statement and any amendment thereto and any Prospectus forming part thereof and any amendment or
supplement thereto complies in all material respects with the Act and the rules and regulations thereunder; and 

(ii) any Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. 
 (c) The Issuers shall advise you, the Holders of Securities or Exchange Securities covered by any Shelf Registration Statement and any Exchanging Dealer under any Exchange Offer Registration Statement
that has provided in writing to any Issuer a telephone or facsimile number and address for notices, and, if requested by you or any such Holder or Exchanging Dealer, shall confirm such advice in writing (which notice pursuant to clauses
(ii)-(v) hereof shall be accompanied by an instruction to suspend the use of the Prospectus until the Issuers shall have remedied the basis for such suspension): 

(i) when a Registration Statement and any amendment thereto has been filed with the Commission and when the Registration
Statement or any post-effective amendment thereto has become effective; 
 (ii) of any request by the Commission
for any amendment or supplement to the Registration Statement or the Prospectus or for additional information; 

(iii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for that purpose; 
 (iv) of the receipt by any Issuer of any notification with
respect to the suspension of the qualification of the securities included therein for sale in any jurisdiction or the initiation of any proceeding for such purpose; and 

(v) of the happening of any event that requires any change in the Registration Statement or the Prospectus so that, as of
such date, the statements therein are not misleading 

  
 -8-

 
and do not omit to state a material fact required to be stated therein or necessary to make the statements therein (in the case of the Prospectus, in the light of the circumstances under which
they were made) not misleading. 
 (d) The Issuers shall use their reasonable best efforts to obtain the
withdrawal of any order suspending the effectiveness of any Registration Statement or the qualification of the securities therein for sale in any jurisdiction at the earliest possible time. 

(e) The Issuers shall furnish to each Holder of Securities or Exchange Securities covered by any Shelf Registration
Statement, without charge, at least one copy of such Shelf Registration Statement and any post-effective amendment thereto, including all material incorporated therein by reference, and, if the Holder so requests in writing, all exhibits thereto
(including exhibits incorporated by reference therein). 
 (f) The Issuers shall, during the Shelf Registration
Period, deliver to each Holder of Securities or Exchange Securities covered by any Shelf Registration Statement, without charge, as many copies of the Prospectus (including each preliminary Prospectus) included in such Shelf Registration Statement
and any amendment or supplement thereto as such Holder may reasonably request. The Issuers consent to the use of the Prospectus or any amendment or supplement thereto by each of the selling Holders of securities in connection with the offering and
sale of the securities covered by the Prospectus, or any amendment or supplement thereto, included in the Shelf Registration Statement. 
 (g) The Issuers shall furnish to each Exchanging Dealer which so requests, without charge, at least one copy of the Exchange Offer Registration Statement and any post-effective amendment thereto,
including all material incorporated by reference therein, and, if the Exchanging Dealer so requests in writing, all exhibits thereto (including exhibits incorporated by reference therein). 

(h) The Issuers shall promptly deliver to each Initial Purchaser, each Exchanging Dealer and each other Person required to
deliver a Prospectus during the Exchange Offer Registration Period, without charge, as many copies of the Prospectus included in such Exchange Offer Registration Statement and any amendment or supplement thereto as any such Person may reasonably
request. The Issuers consent to the use of the Prospectus or any amendment or supplement thereto by any Initial Purchaser, any Exchanging Dealer and any such other Person that may be required to deliver a Prospectus following the Registered Exchange
Offer in connection with the offering and sale of the Exchange Securities covered by the Prospectus, or any amendment or supplement thereto, included in the Exchange Offer Registration Statement. 

(i) Prior to the Registered Exchange Offer or any other offering of Securities or Exchange Securities pursuant to any
Registration Statement, the Issuers shall arrange, if necessary, for the qualification of the Securities or the Exchange Securities for sale under the laws of such jurisdictions as any Holder shall reasonably request and will maintain such
qualification in effect so long as required; provided that in no event shall any Issuer be obligated to qualify to do business in any jurisdiction where it is not then so qualified or to take any action that would subject it to service of
process in suits, other than those arising out of the Initial Placement, the Registered Exchange Offer or any offering pursuant to a Shelf Registration Statement, in any such jurisdiction where it is not then so subject. 

(j) The Issuers shall cooperate with the Holders to facilitate the timely preparation and delivery of certificates
representing Exchange Securities or Securities to be issued or sold pursuant to 

  
 -9-

 
any Registration Statement free of any restrictive legends and in such denominations and registered in such names as Holders may request. 

(k) Upon the occurrence of any event contemplated by subsections (c)(ii) through (v) above, the Issuers shall
promptly prepare a post-effective amendment to the applicable Registration Statement or an amendment or supplement to the related Prospectus or file any other required document so that, as thereafter delivered to purchasers of the Securities
included therein, the Prospectus will not include an untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. In
such circumstances, the period of effectiveness of the Exchange Offer Registration Statement provided for in Section 2 hereof and the Shelf Registration Statement provided for in Section 3(b) hereof shall each be extended by the number of
days from and including the date of the giving of a notice of suspension pursuant to Section 4(c) hereof to and including the date when the Initial Purchasers, the Holders and any known Exchanging Dealer shall have received such amended or
supplemented Prospectus pursuant to this Section 4. 
 (l) Not later than the effective date of any
Registration Statement, the Issuers shall provide CUSIP and ISIN numbers for the Securities or the Exchange Securities, as the case may be, registered under such Registration Statement and provide the Trustee with printed certificates for such
Securities or Exchange Securities, in a form eligible for deposit with The Depository Trust Company. 
 (m) The
Issuers shall comply with all applicable rules and regulations of the Commission and shall make generally available to its security holders as soon as practicable after the effective date of the applicable Registration Statement an earnings
statement satisfying the provisions of Section 11(a) of the Act. 
 (n) The Issuers shall cause the
Indenture to be qualified under the Trust Indenture Act in a timely manner. 
 (o) The Notes Issuers may require
each Holder of securities to be sold pursuant to any Shelf Registration Statement to furnish to the Notes Issuers such information regarding the Holder and the distribution of such securities as the Notes Issuers may from time to time reasonably
require for inclusion in such Registration Statement. The Notes Issuers may exclude from such Shelf Registration Statement the Securities or Exchange Securities of any Holder that fails to furnish such information within a reasonable time after
receiving such request. 
 (p) In the case of any Shelf Registration Statement, the Issuers shall enter into such
and take all other appropriate actions (including if requested an underwriting agreement in customary form) in order to expedite or facilitate the registration or the disposition of the Securities or Exchange Securities, and in connection therewith,
if an underwriting agreement is entered into, cause the same to contain indemnification provisions and procedures no less favorable than those set forth in Section 6 (or such other provisions and procedures acceptable to the Majority Holders
and the Managing Underwriters, if any, with respect to all parties to be indemnified pursuant to Section 6. 

(q) In the case of any Shelf Registration Statement, the Issuers shall: 

(i) make reasonably available for inspection by a representative for the Holders of Securities or Exchange Securities to
be registered thereunder, which representative shall be selected by the Majority Holders, by the underwriters, if any, participating in any disposition pursuant to such Shelf Registration Statement, and by any attorney, accountant or other agent

  
 -10-

 
for the Holders retained by the Majority Holders or for the underwriters, if any, all relevant financial and other records, pertinent corporate documents and properties of each Issuer and its
subsidiaries; 
 (ii) cause the officers, directors and employees of each Issuer to supply all relevant
information reasonably requested by the representative for the Holders, by the underwriters, if any, or by any such attorney, accountant or agent in connection with any such Shelf Registration Statement as is customary for similar due diligence
examinations; provided, however, that any information that is designated in writing by any Issuer, in good faith, as confidential at the time of delivery of such information shall be kept confidential by the Holders, the underwriters,
if any, and any such attorney, accountant or agent, unless such disclosure is made in connection with a court proceeding or required by law, or such information becomes available to the public generally or through a third party without an
accompanying obligation of confidentiality; 
 (iii) make such representations and warranties to the Holders of
Securities or Exchange Securities registered thereunder and the underwriters, if any, in form, substance and scope as are customarily made by issuers to underwriters in primary underwritten offerings and covering matters including, but not limited
to, those set forth in the Purchase Agreement; 
 (iv) obtain opinions of counsel to the Issuers (which counsel
and opinions (in form, scope and substance) shall be reasonably satisfactory to the Managing Underwriters, if any, addressed to each selling Holder and the underwriters, if any, covering such matters as are customarily covered in opinions requested
in underwritten offerings and such other matters as may be reasonably requested by such Holders and underwriters; 
 (v) obtain “cold comfort” letters from the independent certified public accountants of the Issuers (and, if necessary, any other independent certified public accountants of any Issuer or any
subsidiary of any Issuer or of any business acquired by any Issuer for which financial statements and financial data are, or are required to be, included in the Shelf Registration Statement), addressed to each selling Holder of securities registered
thereunder and the underwriters, if any, in customary form and covering matters of the type customarily covered in “cold comfort” letters in connection with primary underwritten offerings; and 

(vi) deliver such documents and certificates as may be reasonably requested by the Majority Holders and the Managing
Underwriters, if any, including those to evidence compliance with Section 4(k) and with any customary conditions contained in the underwriting agreement or other agreement entered into by the Issuers. 

The actions set forth in clauses (iii), (iv), (v) and (vi) of this Section 4(q) shall be performed at (A) the
effectiveness of such Shelf Registration Statement and each post-effective amendment thereto; and (B) each closing under any underwriting or similar agreement as and to the extent required thereunder. 

(r) In the case of any Exchange Offer Registration Statement, upon the request of any Initial Purchaser, the Issuers
shall: 
 (i) make reasonably available for inspection by the Initial Purchasers, and any attorney, accountant or
other agent retained by the Initial Purchasers, all relevant financial and other records, pertinent corporate documents and properties of the Issuers and their respective subsidiaries; 

  
 -11-

 (ii) cause the officers, directors and employees of each Issuer to supply
all relevant information reasonably requested by any Initial Purchaser or any attorney, accountant or agent retained by the Initial Purchasers in connection with any such Exchange Offer Registration Statement as is customary for similar due
diligence examinations; provided, however, that any information that is designated in writing by any Issuer, in good faith, as confidential at the time of delivery of such information shall be kept confidential by such Initial Purchaser or any such
attorney, accountant or agent, unless such disclosure is made in connection with a court proceeding or required by law, or such information becomes available to the public generally or through a third party without an accompanying obligation of
confidentiality; 
 (iii) make such representations and warranties to the Initial Purchasers, in form, substance
and scope as are customarily made by issuers to underwriters in primary underwritten offerings and covering matters including, but not limited to, those set forth in the Purchase Agreement; 

(iv) obtain opinions of counsel to the Issuers (which counsel and opinions (in form, scope and substance) shall be
reasonably satisfactory to the Initial Purchasers and their counsel, addressed to the Initial Purchasers, covering such matters as are customarily covered in opinions requested in underwritten offerings and such other matters as may be reasonably
requested by the Initial Purchasers or their counsel; 
 (v) obtain “cold comfort” letters from the
independent certified public accountants of the Issuers (and, if necessary, any other independent certified public accountants of any Issuer or any subsidiary of any Issuer or of any business acquired by any Issuer for which financial statements and
financial data are, or are required to be, included in the Exchange Offer Registration Statement), addressed to the Initial Purchasers, in customary form and covering matters of the type customarily covered in “cold comfort” letters in
connection with primary underwritten offerings, or if requested by the Initial Purchasers or their counsel in lieu of a “cold comfort” letter, an agreed-upon procedures letter under Statement on Auditing Standards No. 35, covering
matters requested by the Initial Purchasers or their counsel; and 
 (vi) deliver such documents and certificates
as may be reasonably requested by the Initial Purchasers or their counsel, including those to evidence compliance with Section 4(k) and with conditions customarily contained in underwriting agreements. 

The foregoing actions set forth in clauses (iii), (iv), (v), and (vi) of this Section 4(r) shall be performed at
the close of the Registered Exchange Offer and the effective date of any post-effective amendment to the Exchange Offer Exchange Offer Registration Statement. 
 (s) If a Registered Exchange Offer is to be consummated, upon delivery of the Securities by Holders to the Notes Issuers (or to such other Person as directed by the Notes Issuers) in exchange for the
Exchange Securities, the Notes Issuers shall mark, or caused to be marked, on the Securities so exchanged that such Securities are being canceled in exchange for the Exchange Securities. In no event shall the Securities be marked as paid or
otherwise satisfied. 
 (t) The Issuers will use their reasonable best efforts (i) if the Securities have
been rated prior to the initial sale of such Securities, to confirm such ratings will apply to the Securities or the Exchange Securities, as the case may be, covered by a Exchange Offer Registration Statement; or (ii) if the Securities were not
previously rated, to cause the Securities covered by a Registration Statement to 

  
 -12-

 
be rated with at least one nationally recognized statistical rating agency, if so requested by Majority Holders with respect to the related Registration Statement or by any Managing Underwriters.

 (u) In the event that any Broker-Dealer shall underwrite any Securities or Exchange Securities or participate
as a member of an underwriting syndicate or selling group or “assist in the distribution” (within the meaning of the Financial Industry Regulatory Authority, Inc. (the “Conduct Rules”)) thereof, whether as a Holder or as
an underwriter, a placement or sales agent or a broker or dealer in respect thereof, or otherwise, the Issuers shall assist such Broker-Dealer in complying with the requirements of such Conduct Rules, including, without limitation, by: 

(i) if such Conduct Rules shall so require, engaging a “qualified independent underwriter” (as defined in such
Conduct Rules) to participate in the preparation of the Registration Statement, to exercise usual standards of due diligence with respect thereto and, if any portion of the offering contemplated by such Registration Statement is an underwritten
offering or is made through a placement or sales agent, to recommend the yield of such Securities or Exchange Securities; 
 (ii) indemnifying any such qualified independent underwriter to the extent of the indemnification of underwriters provided in Section 6 hereof; and 

(iii) providing such information to such Broker-Dealer as may be required in order for such Broker-Dealer to comply with
the requirements of such Conduct Rules. 
 (v) The Issuers shall use their reasonable best efforts to take all
other steps necessary to effect the registration of the Securities or the Exchange Securities, as the case may be, covered by a Registration Statement. 
 5. Registration Expenses. The Issuers shall bear all expenses incurred in connection with the performance of their obligations under Sections 2, 3 and 4 hereof and, in the event of any Shelf
Registration Statement, will reimburse the Holders for the reasonable fees and disbursements of one firm or counsel designated by the Majority Holders to act as counsel for the Holders in connection therewith, and, in the case of any Exchange Offer
Registration Statement, will reimburse the Initial Purchasers for the reasonable fees and disbursements of counsel acting in connection therewith. 
 6. Indemnification and Contribution. 
 (a) The Issuers, jointly and
severally, agree to indemnify and hold harmless each Holder of Securities or Exchange Securities, as the case may be, covered by any Registration Statement (including each Initial Purchaser and each Affiliate thereof and, with respect to any
Prospectus delivery as contemplated in Section 4(h) hereof, each Exchanging Dealer), the directors, officers, employees and agents of each such Holder and each person who controls any such Holder within the meaning of either the Act or the
Exchange Act against any and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common law or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement as
originally filed or in any amendment thereof, or in any preliminary Prospectus or the Prospectus, or in any amendment thereof or supplement thereto, or arise out of or are based upon the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, and to reimburse each such indemnified party, as incurred, for any legal or other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, 

  
 -13-

 
liability or action; provided, however, that the Issuers will not be liable in any case to the extent that any such loss, claim, damage or liability arises out of or is based upon any such untrue
statement or alleged untrue statement or omission or alleged omission made therein in reliance upon and in conformity with written information furnished to the Notes Issuers by or on behalf of any such Holder specifically for inclusion therein;
provided, further, that with respect to any untrue statement or omission of material fact made in any preliminary Prospectus, the indemnity agreement contained in this Section 6 shall not inure to the benefit of any Holder from whom the Person
asserting any such loss, claim, damage or liability purchased such Securities or Exchange Securities, as the case may be, to the extent that any such loss, claim, damage or liability of such Holder occurs under the circumstance where it shall have
been determined by a court of competent jurisdiction by final and nonappealable judgment that (w) the Notes Issuers had previously furnished copies of the Prospectus to such Holder, (x) delivery of the Prospectus was required by the Act to
be made to such Person, (y) the untrue statement or omission of a material fact contained in the preliminary Prospectus was corrected in the Prospectus and (z) there was not sent or given to such Person, at or prior to the written
confirmation of the sale of such securities to such Person, a copy of the Prospectus. This indemnity agreement will be in addition to any liability which the Issuers may otherwise have. 

The Issuers also, jointly and severally, agree to indemnify or contribute as provided in Section 6(d) to Losses of each underwriter
of Securities or Exchange Securities, as the case may be, registered under a Shelf Registration Statement, their directors, officers, employees or agents and each person who controls such underwriter on substantially the same basis as that of the
indemnification of the Initial Purchasers and the selling Holders provided in this Section 6(a) and shall, if requested by any Holder, enter into an underwriting agreement reflecting such agreement, as provided in Section 4(p) hereof.

 (b) Each Holder of securities covered by a Registration Statement (including each Initial Purchaser and each Affiliate
thereof and, with respect to any Prospectus delivery as contemplated in Section 4(h) hereof, each Exchanging Dealer) severally and not jointly agrees to indemnify and hold harmless the Issuers, each of their respective directors, each of their
respective officers who signs such Registration Statement, and each person who controls any Issuer within the meaning of either the Act or the Exchange Act, to the same extent as the foregoing indemnity from the Issuers to each such Holder, but only
with reference to written information relating to such Holder furnished to the Issuers by or on behalf of such Holder specifically for inclusion in the documents referred to in the foregoing indemnity. This indemnity agreement will be in addition to
any liability which any such Holder may otherwise have. 
 (c) Promptly after receipt by an indemnified party under this
Section 6 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 6, notify the indemnifying party in writing of the
commencement thereof; but the failure so to notify the indemnifying party (i) will not relieve it from liability under paragraph (a) or (b) above unless and to the extent it did not otherwise learn of such action and such failure
results in the forfeiture by the indemnifying party of substantial rights and defenses; and (ii) will not, in any event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation
provided in paragraph (a) or (b) above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified party in any action for which
indemnification is sought (in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by the indemnified party or parties except as set forth below); provided,
however, that such counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the indemnifying party’s election to appoint counsel to represent the indemnified party in an action, the indemnified party shall have
the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (i) the use of counsel chosen by the indemnifying party to represent the
indemnified party would present such counsel with a conflict of interest; (ii) the actual or potential defendants in, or targets of, any such action include both the 

  
 -14-

 
indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are
different from or additional to those available to the indemnifying party; (iii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time
after notice of the institution of such action; or (iv) the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. An indemnifying party will not, without the prior written
consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder
(whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such claim,
action, suit or proceeding. An indemnifying party shall not be liable under this Section 6 to any indemnified party regarding any settlement or compromise or consent to the entry of any judgment with respect to any pending or threatened claim,
action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent is
consented to by such indemnifying party, which consent shall not be unreasonably withheld. 
 (d) In the event that the
indemnity provided in paragraph (a) or (b) of this Section 6 is unavailable to or insufficient to hold harmless an indemnified party for any reason, then each applicable indemnifying party shall have a joint and several obligation to
contribute to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating or defending same) (collectively “Losses”) to which such indemnified party
may be subject in such proportion as is appropriate to reflect the relative benefits received by such indemnifying party, on the one hand, and such indemnified party, on the other hand, from the Initial Placement and the Registration Statement which
resulted in such Losses; provided, however, that in no case shall any Initial Purchaser or any subsequent Holder of any Security or Exchange Security be responsible, in the aggregate, for any amount in excess of the purchase discount
or commission applicable to such Security, or in the case of an Exchange Security, applicable to the Security that was exchangeable into such Exchange Security, as set forth on the cover page of the Final Memorandum, nor shall any underwriter be
responsible for any amount in excess of the underwriting discount or commission applicable to the securities purchased by such underwriter under the Registration Statement which resulted in such Losses. If the allocation provided by the immediately
preceding sentence is unavailable for any reason, the indemnifying party and the indemnified party shall contribute in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of such indemnifying
party, on the one hand, and such indemnified party, on the other hand, in connection with the statements or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Issuers shall be
deemed to be equal to the sum of (x) the total net proceeds from the Initial Placement (before deducting expenses or original issue discount) as set forth on the cover page of the Final Memorandum and (y) the total amount of additional
interest which the Issuers were not required to pay as a result of registering the securities covered by the Registration Statement which resulted in such Losses. Benefits received by the Initial Purchasers shall be deemed to be equal to the total
purchase discounts and commissions as set forth on the cover page of the Final Memorandum, and benefits received by any other Holders shall be deemed to be equal to the value of receiving Securities or Exchange Securities, as applicable, registered
under the Act. Benefits received by any underwriter shall be deemed to be equal to the total underwriting discounts and commissions, as set forth on the cover page of the Prospectus forming a part of the Registration Statement which resulted in such
Losses. Relative fault shall be determined by reference to, among other things, whether any untrue or alleged untrue statement of or omission or alleged omission to state a material fact relates to information provided by the indemnifying party, on
the one hand, or by the indemnified party, on the other hand, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The parties agree that it would not
be just and equitable if contribution were determined by pro rata allocation (even if the Holders were treated as one entity for such purpose) or any other method of allocation which does not take account of the equitable considerations referred to
above. Notwithstanding the provisions of this paragraph (d), 

  
 -15-

 
no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section 6, each person who controls a Holder within the meaning of either the Act or the Exchange Act and each director, officer, employee and agent of such Holder shall have the same rights to
contribution as such Holder, and each person who controls any Issuer within the meaning of either the Act or the Exchange Act, each officer of any Issuer who shall have signed the Registration Statement and each director of any Issuer shall have the
same rights to contribution as the Issuers, subject in each case to the applicable terms and conditions of this paragraph (d). 

(e) The provisions of this Section 6 will remain in full force and effect, regardless of any investigation made by or on behalf of
any Holder or the Issuers or any of the officers, directors or controlling Persons referred to in this Section 6 hereof, and will survive the sale by a Holder of securities covered by a Registration Statement. 

7. Underwritten Registrations. 
 (a) If any of the Securities or Exchange Securities, as the case may be, covered by any Shelf Registration Statement are to be sold in an underwritten offering, the Managing Underwriters shall be selected
by the Majority Holders. 
 (b) No Person may participate in any underwritten offering pursuant to any Shelf Registration
Statement, unless such Person (i) agrees to sell such Person’s Securities or Exchange Securities, as the case may be, on the basis reasonably provided in any underwriting arrangements approved by the Persons entitled hereunder to approve
such arrangements; and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements. 

8. Registration Defaults. The Issuers and the Initial Purchasers agree that the Holders will suffer damages if the Issuers fail to
fulfill their obligations under Section 2 or Section 3 hereof and that it would not be feasible to ascertain the extent of such damages with precision. Accordingly, the Issuers agree to pay, jointly and severally, as liquidated damages,
additional interest on the Notes (“Additional Interest”) under the circumstances and to the extent set forth below (each of which shall be given independent effect): 

(a) the Registered Exchange Offer is not completed on or prior to the 360th day after the Issue Date, then commencing on
the day after such date, Additional Interest shall accrue on the principal amount of the Securities at a rate of 0.25% per annum for the first 90 days immediately following each date, such Additional Interest rate increasing by an additional
0.25% per annum at the beginning of each subsequent 90-day period; or 
 (b) the Issuers are required by
Section 3(a) hereof to file a Shelf Registration Statement and (i) such Shelf Registration Statement is not filed with the Commission by the date required by Section 3(b) hereof or (ii) such Shelf Registration Statement is not
declared effective by the Commission on or prior to the 60th day following the date such Shelf Registration Statement was filed, then, commencing on the day after either such required date, Additional Interest shall accrue on the principal amount of
the Securities at a rate of 0.25% per annum for the first 90 days immediately following such date, such Additional Interest rate increasing by an additional 0.25% per annum at the beginning of each subsequent 90-day period; or 

(c) if applicable, the Shelf Registration Statement has been declared effective and such Shelf Registration Statement
ceases to be effective at any time prior to the one year anniversary of its 

  
 -16-

 
effective date prior to all Securities covered by the Shelf Registration Statement have been sold, then Additional Interest shall accrue on the principal amount of the Securities at a rate of
0.25% per annum for the first 90 days commencing on the day such Shelf Registration Statement ceases to be effective, such Additional Interest rate increasing by an additional 0.25% per annum at the beginning of each subsequent 90-day
period; 
 (each such event referred to in (a), (b) and (c), a “Registration Default”), provided, however,
that the Additional Interest rate on the Securities shall not accrue under more than one Registration Default at any one time and at no time shall the aggregate amount of Additional Interest accruing exceed in the aggregate 1.0% per annum;
provided, further, however, that (1) upon the completion of the Registered Exchange Offer (in the case of clause (a) above), (2) upon the filing of the Shelf Registration Statement (in the case of clause
(b)(i) above) or upon the effectiveness of the Shelf Registration Statement (in the case of clause (b)(ii) above), or (3) upon the effectiveness of the Shelf Registration Statement which had ceased to remain effective (in the case of
clause (c)above), Additional Interest on the Securities as a result of such clause (or the relevant subclause thereof), as the case may be, shall cease to accrue. Any amounts of Additional Interest due as a result of a Registration Default shall be
payable in cash on the same original interest payment dates as the Securities. 
 9. No Inconsistent Agreements. No
Issuer has, as of the date hereof, entered into, nor shall it, on or after the date hereof, enter into, any agreement with respect to its securities that is inconsistent with the rights granted to the Holders herein or otherwise conflicts with the
provisions hereof. 
 10. Amendments and Waivers. The provisions of this Agreement, including the provisions of this
sentence, may not be amended, qualified, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the Issuers have obtained the written consent of the Majority Holders; provided that, with
respect to any matter that directly or indirectly affects the rights of any Initial Purchaser hereunder, the Issuers shall obtain the written consent of each Initial Purchaser against which such amendment, qualification, supplement, waiver or
consent is to be effective provided, further, that no amendment, qualification, supplement, waiver or consent with respect to Section 8 hereof shall be effective as against any Holder of Securities unless consented to in writing by such Holder;
and provided, further, that the provisions of this Article 10 may not be amended, qualified, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the Issuers have obtained the written
consent of the Initial Purchasers and each Holder. Notwithstanding the foregoing (except the foregoing proviso), a waiver or consent to departure from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders
whose Securities or Exchange Securities, as the case may be, are being sold pursuant to a Registration Statement and that does not directly or indirectly affect the rights of other Holders may be given by the Majority Holders, determined on the
basis of Securities or Exchange Securities, as the case may be, being sold rather than registered under such Registration Statement. 
 11. Notices. All notices and other communications provided for or permitted hereunder shall be made in writing by hand-delivery, first-class mail, telex, telecopier or air courier guaranteeing
overnight delivery: 
 (a) if to a Holder, at the most current address given by such holder to the Issuers in
accordance with the provisions of this Section 10, which address initially is, with respect to each Holder, the address of such Holder maintained by the Registrar under the Indenture, with a copy in like manner to Deutsche Bank Securities Inc.;

 (b) if to you, initially at the respective addresses set forth in the Purchase Agreement; and 

(c) if to the Issuers, initially at their address set forth in the Purchase Agreement. 

  
 -17-

 All such notices and communications shall be deemed to have been duly given when received.

 The Initial Purchasers or the Issuers by notice to the other parties may designate additional or different addresses for
subsequent notices or communications. 
 12. Successors. This Agreement shall inure to the benefit of and be binding upon
the successors and assigns of each of the parties hereto, including, without the need for an express assignment or any consent by the Issuers thereto, subsequent Holders of Securities and the Exchange Securities. The Issuers hereby agree to extend
the benefits of this Agreement to any Holder of Securities or the Exchange Securities, and any such Holder may specifically enforce the provisions of this Agreement as if an original party hereto. 

13. Counterparts. This Agreement may be in signed counterparts, each of which shall an original and all of which together shall
constitute one and the same agreement. 
 14. Headings. The headings used herein are for convenience only and shall not
affect the construction hereof. 
 15. Applicable Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be performed in the State of New York. 
 16.
Severability. In the event that any one of more of the provisions contained herein, or the application thereof in any circumstances, is held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and
enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired or affected thereby, it being intended that all of the rights and privileges of the parties shall be enforceable to
the fullest extent permitted by law. 
 17. Securities Held by the Issuers, etc. Whenever the consent or approval of
Holders of a specified percentage of principal amount of Securities or Exchange Securities is required hereunder, Securities or Exchange Securities, as applicable, held by any Issuer or its Affiliates (other than subsequent Holders of Securities or
Exchange Securities if such subsequent Holders are deemed to be Affiliates solely by reason of their holdings of such Securities or Exchange Securities) shall not be counted in determining whether such consent or approval was given by the Holders of
such required percentage. 

  
 -18-

 If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this Agreement and your acceptance shall represent a binding agreement among the Issuers and the several Initial Purchasers. 

 

					
	Very truly yours,
	
	Crown Holdings, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Attest:
		
	By:	 	/s/ William T. Gallagher
		 	Name:	 	William T. Gallagher
		 	Title:	 	Secretary and General Counsel
	
	Crown Americas LLC
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Americas Capital Corp. III
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer

 
					
	GUARANTORS:
	
	 Central States Can Co. of Puerto Rico, Inc.
 CROWN Beverage Packaging Puerto Rico, Inc.
 Crown Consultants, Inc.

Crown Cork & Seal Company (DE), LLC

Crown Cork & Seal Company, Inc.
 Crown
Financial Corporation
 Crown Financial Management, Inc.
 Crown International Holdings, Inc.
 CROWN Packaging Technology, Inc.

Foreign Manufacturers Finance Corporation
 NWR,
Inc.
 Crown Beverage Packaging, LLC

CROWN Cork & Seal USA, Inc.
 CR USA,
Inc.

	
	Central States Can Co. of Puerto Rico, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	CROWN Beverage Packaging Puerto Rico, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer

 
					
	Crown Consultants, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Cork & Seal Company (DE), LLC
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Cork & Seal Company, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Financial Corporation
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Financial Management, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer

 
					
	Crown International Holdings, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	CROWN Packaging Technology, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Foreign Manufacturers Finance Corporation
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	NWR, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Vice President and Treasurer
	
	Crown Beverage Packaging, LLC
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Assistant Treasurer

 
					
	CROWN Cork & Seal USA, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Assistant Treasurer
	
	CR USA, Inc.
		
	By:	 	/s/ Michael B. Burns
		 	Name:	 	Michael B. Burns
		 	Title:	 	Assistant Treasurer

					
	 The foregoing Agreement is hereby confirmed
 and accepted as of the date first above written.

	
	DEUTSCHE BANK SECURITIES INC.
		
	By:	 	/s/ Edwin Roland
		 	Name:	 	Edwin Roland
		 	Title:	 	Managing Director
		
	By:	 	/s/ Scott Sartorius
		 	Name:	 	Scott Sartorius
		 	Title:	 	Managing Director

 For themselves and the other several
Initial 
 Purchasers named in Schedule I to the 
 foregoing Agreement. 

  
 -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]